EP3095796A1 - Anti-human probdnf monoclonal antibody, and uses thereof in pains - Google Patents
Anti-human probdnf monoclonal antibody, and uses thereof in pains Download PDFInfo
- Publication number
- EP3095796A1 EP3095796A1 EP15737195.6A EP15737195A EP3095796A1 EP 3095796 A1 EP3095796 A1 EP 3095796A1 EP 15737195 A EP15737195 A EP 15737195A EP 3095796 A1 EP3095796 A1 EP 3095796A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pain
- antibody
- antibody polypeptide
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 78
- 230000036407 pain Effects 0.000 title claims abstract description 59
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 65
- 229920001184 polypeptide Polymers 0.000 claims abstract description 64
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 64
- 150000001413 amino acids Chemical class 0.000 claims abstract description 30
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 17
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims abstract description 13
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 208000000094 Chronic Pain Diseases 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 9
- 239000013598 vector Substances 0.000 claims description 39
- 230000001684 chronic effect Effects 0.000 claims description 32
- 206010065390 Inflammatory pain Diseases 0.000 claims description 22
- 208000009935 visceral pain Diseases 0.000 claims description 12
- 230000001154 acute effect Effects 0.000 claims description 11
- 239000007928 intraperitoneal injection Substances 0.000 claims description 11
- 206010003246 arthritis Diseases 0.000 claims description 10
- 206010058019 Cancer Pain Diseases 0.000 claims description 9
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 9
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 9
- 206010016059 Facial pain Diseases 0.000 claims description 9
- 208000019695 Migraine disease Diseases 0.000 claims description 9
- 208000004983 Phantom Limb Diseases 0.000 claims description 9
- 206010056238 Phantom pain Diseases 0.000 claims description 9
- 206010027599 migraine Diseases 0.000 claims description 9
- 208000004296 neuralgia Diseases 0.000 claims description 9
- 208000021722 neuropathic pain Diseases 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 9
- 208000004550 Postoperative Pain Diseases 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 abstract description 52
- 102000004169 proteins and genes Human genes 0.000 abstract description 29
- 239000002243 precursor Substances 0.000 abstract description 18
- 229940079593 drug Drugs 0.000 abstract description 6
- 241000700159 Rattus Species 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 36
- 101500024763 Homo sapiens BDNF precursor form Proteins 0.000 description 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 32
- 239000012634 fragment Substances 0.000 description 29
- 238000002474 experimental method Methods 0.000 description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 24
- 239000006228 supernatant Substances 0.000 description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 239000000427 antigen Substances 0.000 description 19
- 108091007433 antigens Proteins 0.000 description 19
- 102000036639 antigens Human genes 0.000 description 19
- 238000000034 method Methods 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 230000027455 binding Effects 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 238000002347 injection Methods 0.000 description 17
- 239000011780 sodium chloride Substances 0.000 description 16
- 238000005520 cutting process Methods 0.000 description 15
- 230000004044 response Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 210000002683 foot Anatomy 0.000 description 13
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- 241001529936 Murinae Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 9
- 108010025020 Nerve Growth Factor Proteins 0.000 description 8
- 108010022394 Threonine synthase Proteins 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 102000004419 dihydrofolate reductase Human genes 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 210000002414 leg Anatomy 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 210000003462 vein Anatomy 0.000 description 8
- 241000283707 Capra Species 0.000 description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 208000005298 acute pain Diseases 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 102000015336 Nerve Growth Factor Human genes 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 6
- 208000000114 Pain Threshold Diseases 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000037040 pain threshold Effects 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 229940035676 analgesics Drugs 0.000 description 5
- 239000000730 antalgic agent Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 210000000548 hind-foot Anatomy 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 229940053128 nerve growth factor Drugs 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000011514 reflex Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 206010064012 Central pain syndrome Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 239000003593 chromogenic compound Substances 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000020796 long term synaptic depression Effects 0.000 description 3
- 230000027928 long-term synaptic potentiation Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000003405 preventing effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 101150035467 BDNF gene Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101500028017 Mus musculus BDNF precursor form Proteins 0.000 description 2
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 239000012930 cell culture fluid Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002205 phenol-chloroform extraction Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000009465 prokaryotic expression Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 231100000691 up-and-down procedure Toxicity 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 101800001848 BDNF precursor form Proteins 0.000 description 1
- 102400001309 BDNF precursor form Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000739876 Homo sapiens Brain-derived neurotrophic factor Proteins 0.000 description 1
- 101100273566 Humulus lupulus CCL10 gene Proteins 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- -1 Lilly) Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 102000009609 Pyrophosphatases Human genes 0.000 description 1
- 108010009413 Pyrophosphatases Proteins 0.000 description 1
- 101710086015 RNA ligase Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 238000009960 carding Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000009123 feedback regulation Effects 0.000 description 1
- 210000002391 femur head Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 102000051542 human BDNF Human genes 0.000 description 1
- 229940077456 human brain-derived neurotrophic factor Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000019581 neuron apoptotic process Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000004697 synapse damage Effects 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 229950008160 tanezumab Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- the present invention relates to preparation of a monoclonal antibody against human brain-derived neurotrophic factor precursor protein (proBDNF) and uses of such monoclonal antibody to mitigate and / or inhibit various types of acute and chronic pain, such as post-operative pain, acute inflammatory pain, chronic inflammatory pain, phantom limb pain, painful diabetic neuropathy, neuropathic pain, chronic lumbodorsalgia, chronic visceral pain, cancer pain, arthritis pain, craniofacial pain, trigeminal neuralgia, migraine, complex regional pain syndrome, and the likes.
- proBDNF human brain-derived neurotrophic factor precursor protein
- excessive pain will cause damage to the body, and become one kind of unbearable torture to the body. Therefore, analgesia is an important task for healthcare practitioners.
- Chronic pain threatens the survival and quality of human life, and also causes a great burden on families and society. According to American Pain Society, it was reported that the prevalence of chronic pain in United States was estimated as 35.5%, including 105 million people. It costs over $ 100 billion, directly resulting in the consumption of healthcare spending and the loss of working hours.
- analgesics include acetaminophen, non-steroidal anti-inflammatory drugs and opioid receptor agonists, such as tramadol and morphine.
- Non-steroidal anti-inflammatory drugs NSAIDs
- NSAIDs have weak analgesic efficacy, and may lead to gastrointestinal bleeding, renal failure and liver dysfunction as well as other side effects; and overdose of opioids will cause respiratory depression, and long-term use thereof will lead to side effects, such as constipation, abuse, dependence and addiction.
- analgesics which are also marketed, for example antidepressants (such as Duloxetine, Lilly), anticonvulsants (such as Puri Galindo, Lyrica TM , Pfizer) and selective cyclooxygenase-2 (COX-2) inhibitors (such as Parecoxib, Pfizer).
- antidepressants such as Duloxetine, Lilly
- anticonvulsants such as Puri Galindo, Lyrica TM , Pfizer
- COX-2 selective cyclooxygenase-2
- a new mode for developing analgesic drugs is the mechanism-mediated development of new drug targets.
- the mechanism of pain is mainly studied to find an important factor or target for regulating occurrence and development of pain, thereby developing a new medicament to intervene with the factor or target and achieve analgesia.
- Many clinical applications based on the results of such basic research are currently tested, however, few of them are successful.
- NGF anti-nerve growth factor
- Pfizer Tanezumab
- SAR164877/REGN475 SAR164877/REGN475
- NJ-42160443/AMG403 Johnson & Johnson / Amgen
- phase III in rheumatoid arthritis and ankylosing spondylitis patients for evaluating clinical efficacy and safety of analgesia of anti-NGF antibodies in combination with NSAID drugs
- painless ischemic necrosis of caput femoris can be found in a small number of patients ( Garber K Painkiller Novel Fate of the mAbs Hangs in Balance. Nat Biotechnol 2011, 173-174 ; Seidel M, Lane N, Control of Arthritis Pain with Anti-Nerve-Growth Factor, Risk and Benefit, Curr Rheumatol Rep, 2012, 583-585 ).
- Brain-derived neurotrophic factor BDNF is a neurotrophic factor discovered after nerve growth factor was discovered, molecular weight of which is 12.4 kDa. BNDF mainly distributes in central nervous system, and is also synthesized in peripheral nervous system and plays an important role in the regulation of survival, differentiation of neuron and synaptic plasticity and damage repair. Currently, there is an evidence to show that BDNF is not only an important factor in regulating development of nervous system and emotional disorders, but also an important mediator of pain. Precursor for brain-derived neurotrophic factor (proBDNF) is synthesized in endoplasmic reticulum from BDNF gene through transcription and translation.
- proBDNF brain-derived neurotrophic factor
- the peptide chain is of 247 amino acids in length, and the theoretical molecular weight of the amino acid sequence is 27.8 KD. However, the molecular weight may be varied in a range of 32-36 kD due to different degree of glycosylation for the protein.
- ProBDNF the amino acid sequence at 1-18 positions is signal peptide sequence, and two fragments are produced during secretion process, wherein one fragment is a polypeptide fragment containing amino acids at 19-129 positions (that is, precursor domain), which is called precursor domain (proBDNF pro-domain), and another fragment is a fragment of amino acids at 130-247 positions (that is, mature domain), which will form BDNF with bioactivities upon processing.
- proBDNF is not only an intermediate of mature BDNF, but also can be used as a ligand to bind high-affinity receptor, p75 neurotrophin receptor (p75NTR) for exerting biological effects.
- p75NTR neurotrophin receptor
- spinal sensitization mechanism of pain is similar to forming mechanism of Long-term potentiation (LTP) / long term depression (LTD) of hippocampus, while BDNF-TrkB and proBDNF-p75NTR signaling pathway are important signaling molecules for regulating LTP / LTD.
- both of outer peripheral sensitization and central sensitization can occur, and the difference between which is that: for outer peripheral sensitization, transmitters released by nerve fibers or axons in local tissue and intracellular signaling pathways are different, and pain transmitter and signaling pathways associated with dorsal root ganglion are also different, the latter of which lasts longer; in addition, for central sensitization, sustained activation of glial cells in spinal cord may also be the most important difference between the mechanisms of acute and chronic pain.
- the present invention relates to an antibody polypeptide that specifically recognizes amino acids at positions 19-128 of precursor domain of protein (pro-BDNF pro-domain), including a heavy chain variable region comprising the following amino acid sequence: (a) CDR1 region of SEQ ID NO: 1, CDR2 region of SEQ ID NO: 2, (c) CDR3 region of SEQ ID NO: 3; and / or a light chain variable region comprising the following amino acid sequence: (d) CDR1 region of SEQ ID NO: 4, (e) CDR2 region of SEQ ID NO: 5, (f) CDR3 region of SEQ ID NO: 6.
- a heavy chain variable region comprising the following amino acid sequence: (a) CDR1 region of SEQ ID NO: 1, CDR2 region of SEQ ID NO: 2, (c) CDR3 region of SEQ ID NO: 3; and / or a light chain variable region comprising the following amino acid sequence: (d) CDR1 region of SEQ ID NO: 4, (e) CDR2 region of SEQ ID NO: 5, (
- the antibody polypeptide is a monoclonal antibody.
- the amino acid sequence of heavy chain variable region is SEQ ID NO: 7
- the amino acid sequences of light chain variable region is SEQ ID NO: 8.
- the amino acid sequence of heavy chain is SEQ ID NO: 9
- the amino acid sequence of light chain is SEQ ID NO: 10.
- the antibody polypeptide may be selected from a humanized antibody polypeptide, a chimeric antibody polypeptide, an affinity maturated antibody polypeptide or one or more combinations thereof.
- the antibody polypeptide is an antibody polypeptide competing with the antibody polypeptides as said above.
- the present invention relates to a nucleic acid sequence encoding the antibody polypeptides as said above.
- the nucleic acid encoding the amino acid sequence of heavy chain variable region of the antibody polypeptide is SEQ ID NO: 11
- the nucleic acid encoding the amino acid sequence of light chain variable region of the antibody polypeptide is SEQ ID NO: 12.
- the nucleic acid encoding the amino acid sequence of heavy chain of the antibody polypeptide is SEQ ID NO: 13
- the nucleic acid encoding the amino acid sequence of light chain of the antibody polypeptide is SEQ ID NO: 14.
- the present invention relates to a vector comprising the nucleic acid sequence.
- the present invention relates to a host comprising the vector.
- the present invention relates to a use of one or more of antibody polypeptides specifically recognizing precursor domain of pro-BDNF in preparation of a medicament to mitigate and / or inhibit chronic pain selected from the following group: chronic inflammatory pain, phantom limb pain, painful diabetic neuropathy, neuropathic pain, chronic lumbodorsalgia, chronic visceral pain, cancer pain, arthritis pain, craniofacial pain, trigeminal neuralgia, migraine, complex regional pain syndrome, and a combination thereof.
- chronic pain selected from the following group: chronic inflammatory pain, phantom limb pain, painful diabetic neuropathy, neuropathic pain, chronic lumbodorsalgia, chronic visceral pain, cancer pain, arthritis pain, craniofacial pain, trigeminal neuralgia, migraine, complex regional pain syndrome, and a combination thereof.
- the present invention relates to a use of the antibody polypeptide in preparation of a medicament to mitigate and / or inhibit pain selected from the following group: post-operative pain, acute inflammatory pain, chronic inflammatory pain, phantom limb pain, painful diabetic neuropathy, neuropathic pain, chronic lumbodorsalgia, chronic visceral pain, cancer pain, arthritis pain, craniofacial pain, trigeminal neuralgia, migraine, complex regional pain syndrome, and a combination thereof.
- pain selected from the following group: post-operative pain, acute inflammatory pain, chronic inflammatory pain, phantom limb pain, painful diabetic neuropathy, neuropathic pain, chronic lumbodorsalgia, chronic visceral pain, cancer pain, arthritis pain, craniofacial pain, trigeminal neuralgia, migraine, complex regional pain syndrome, and a combination thereof.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of the antibody polypeptide.
- the pharmaceutical composition is administered by intravenous or intraperitoneal injection.
- the antibody polypeptide and the corresponding pharmaceutical composition of the present invention are capable of specifically recognizing the precursor domain of proBDNF (pro-domain), inhibiting and / or preventing various types of acute pain or chronic pain, for example, post-operative pain, acute inflammatory pain, chronic inflammatory pain, phantom limb pain, painful diabetic neuropathy, neuropathic pain, chronic lumbodorsalgia, chronic visceral pain, cancer pain, arthritis pain, craniofacial pain, trigeminal neuralgia, migraine, complex regional pain syndrome, and a combination thereof.
- the antibody polypeptide and the corresponding pharmaceutical composition of the present invention can produce technical effects which can not be achieved in the prior art, and possess broad and good prospects for clinical application.
- the anti-proBDNF antibody polypeptide of the present invention can specifically recognizes amino acids at positions 19-128 of precursor domain of pro-BDNF (pro-domain), including a heavy chain variable region comprising the following amino acid sequence: (a) CDR1 region of SEQ ID NO: 1, CDR2 region of SEQ ID NO: 2, (c) CDR3 region of SEQ ID NO: 3; and / or light chain variable region comprising the following amino acid sequence: (d) CDR1 region of SEQ ID NO: 4, (e) CDR2 region of SEQ ID NO: 5, (f) CDR3 region of SEQ ID NO: 6.
- a heavy chain variable region comprising the following amino acid sequence: (a) CDR1 region of SEQ ID NO: 1, CDR2 region of SEQ ID NO: 2, (c) CDR3 region of SEQ ID NO: 3; and / or light chain variable region comprising the following amino acid sequence: (d) CDR1 region of SEQ ID NO: 4, (e) CDR2 region of SEQ ID NO: 5, (f)
- the antibody polypeptides of the present invention not only inhibit and / or prevent various types of acute pain or chronic pain, for example, post-operative pain, acute inflammatory pain, chronic inflammatory pain, phantom limb pain, painful diabetic neuropathy, neuropathic pain, chronic lumbodorsalgia, chronic visceral pain, cancer pain, arthritis pain, craniofacial pain, trigeminal neuralgia, migraine, complex regional pain syndrome, and a combination thereof.
- Antibody polypeptide of the present invention refers to an immunoglobulin molecule, which can specifically recognize target sites, such as polysaccharides, polynucleotides, lipids, polypeptides and the likes, through at least one antigen recognition site in the variable region of the immunoglobulin.
- target sites such as polysaccharides, polynucleotides, lipids, polypeptides and the likes
- antibody polypeptide includes intact polyclonal antibodies and monoclonal antibodies, and also includes fragments thereof, e.g., single chain antibody (scFV), Fd fragment, Fab fragment, F(ab')2 fragment, single domain antibody fragment, isolated CDR fragment and derivatives thereof, such as mutants thereof, or immunoglobulin molecule structure comprising modification of at least one antigen binding site.
- An intact antibody consists of two identical heavy chains and two identical light chains, each of which contains one variable region (V region) and one or more constant region (C region).
- the variable region is responsible for binding to an antigen, and the constant region is primarily responsible for binding an effector.
- CDR complementary determining region
- Other parts of the variable region comprise rigid ⁇ sheet and support so-called framework regions (FRs). CDR and FR are spaced to form a sandwich structure.
- Single-chain antibody (scFV) fragment refers to an antibody fragment constructed by gene engineering, which is a recombinant protein comprising a heavy chain variable region (VH) connecting to a light chain variable region (VL) via a linker, and the two domains are associated via the linker to form an antigen binding site.
- VH heavy chain variable region
- VL light chain variable region
- the size of a scFV is generally 1/6 of a complete antibody.
- Fd fragment refers to an antibody fragment consisting of heavy chain VH and CH1.
- Fab fragment refers to a heterodimer consisting of a Fd fragment (consisting of heavy chain VH and CH1) and an entire light chain formed via inter-chain disulfide bonds.
- the size of "Fab antibody” is 1/3 of an intact antibody, which only contains one antigen binding site.
- F(ab')2 fragment refers to a bivalent fragment comprising two linked Fab fragments.
- Single domain antibody consists of a heavy chain variable region or light chain variable region.
- the antibody fragment is so named since it only consists of one domain.
- the size of the fragment is 1/12 of an intact antibody.
- “Derivatives” include, for example, derivatives of the antibody obtaining by phage display techniques. Efficiency of phage antibodies binding EGFR or CD3 antigen epitope can be increased by, for example, surface plasmon resonance technology used in BIAcore system ( Schier , human antibody hybridomas 7 (1996), 97-105 ; Malmborg , Immunol. Methods., 183 (1995), 7-13 ).
- the method also includes, for example, the preparation method for chimeric antibodies disclosed in WO 89/09622 , the preparation method for humanized antibodies disclosed in EP-A10239400 and WO90/07861 , and the preparation method for xenogeneic antibodies disclosed in WO91/10741 , WO94/02602 and WO96/33735 , for example, preparing human antibodies in mice.
- the antibody or fragments thereof used in the present invention may be further modified by one of the conventional techniques known in the art or combinations thereof, for example, deletions, insertions, substitutions, additions of amino acids, and / or recombination, and / or other modification methods.
- the method for introducing such modification into DNA sequence of an antibody according to the amino acid sequence thereof is well known to a skilled person.
- the antibody or antibody fragment of the present invention may be humanized, chimeric or murine antibody.
- "humanized antibody” refers to an antibody having an amino acid sequence corresponding to an antibody produced by human, and / or an antibody prepared by techniques for preparing humanized antibody known in the art and disclosed in the present application.
- Humanized antibody mainly refers to an antibody from a murine (or other non-human) monoclonal antibody, wherein the murine (or other non-human) monoclonal antibody is modified and re-expressed through gene clone, DNA recombination, and most of amino acid sequence of the murine (or other non-human) monoclonal antibody is replaced by a human sequence.
- Humanized antibodies include chimeric antibodies, modified antibody (also named as CDR grafting antibody), surface re-shaped antibodies or fully humanized antibodies.
- Humanized antibodies may also be produced by a variety of methods known in the art. For example, a humanized antibody can be selected from a phage library expressing humanized antibodies. Humanized antibodies can also be prepared by introducing human immunoglobulin loci in transgenic animals. The transgenic animal can be, for example, a mouse, genes of endogenous immunoglobulin of which have been partially or completely inactivated. Furthermore, humanized antibodies may also be prepared by immortalizing human B lymphocytes producing antibodies against a specific antigen.
- Chimeric antibody refers to an antibody, wherein a portion of the amino acid sequence of heavy chain and light chain is homologous to the corresponding sequence of an antibody from a particular species, while other portions of the chain is homologous to the corresponding sequence from another particular species.
- heavy chain and light chain variable regions are similar to variable regions of a mammalian species, while the constant regions are homologous to the sequence from another mammalian species.
- Advantages of chimeric antibody are that it can be prepared by combining variable regions which can be easily prepared from origins known in the art by using currently available lymphoma cells or B cells of non-human host, and constant regions obtained from, for example a preparation of human cells.
- the specificity of the chimeric antibody is not affected by its origin, since the constant region thereof is human origin and is not likely to cause immune response in a human recipient.
- the definition of chimeric antibody is not limited to the specific examples described herein.
- Modified antibody is also named as CDR grafting antibody, wherein CDR in variable region of an antibody is the region of the antibody to recognize and bind antigen and directly determine the specificity of the antibody.
- CDR of a murine monoclonal antibody is grafted to variable region of a human antibody to replace CDR of the human antibody, therefore, the obtained human antibody will possess antigen-binding specificity of the murine monoclonal antibody and reduced heterogenicity.
- an antigen mainly contacts with CDR of an antibody
- FR region will generally be involved, thereby influencing spatial configuration of CDR.
- FR region is changed to human FR region
- configuration of CDR of the original monoclonal antibody may be altered due to V region formed by such interchimeric murine CDR and human FR, and capability of binding an antigen will be reduced or even significantly reduced.
- an antibody can be designed at molecular level, certain key residues in murine FR region can be introduced into human FR region, and if properly configured, affinity of the obtained antibody is comparable with that of the original murine antibody.
- surface re-shaped antibody refers to an antibody obtained from humanized modification to surface amino acid residues of a heterologous antibody.
- Fully humanized antibody refers to such antibody, which is obtained by transferring an antibody-encoding gene of human into a genetically engineered antibody gene-deleted animal through transgenic or chromosome transfer technology, and the animal expresses human antibodies, thereby obtaining fully humanized antibodies.
- an antibody polypeptide competing with the antibody polypeptide of the present invention may include, for example, an antibody polypeptide with similar and / or identical antigen-binding properties obtained by conservatively replacing one or more amino acids in CDR regions (CDR1, CDR2, CDR3) of heavy chain and / or light chain variable region of an antibody polypeptide or one or more amino acids in frame regions of an antibody polypeptide through genetic engineering methods known in the art.
- the present invention relates to a vector comprising a nucleotide sequence encoding the above polypeptide.
- the vector can be an eukaryotic vector or a prokaryotic vector, as long as the vector satisfies the following requirements: (a) coding sequence of the vector contains the sequence for replication initiation, so that the vector can be replicated in a host cell, (b) the vector comprises a gene sequence encoding a selectable marker, and the protein encoded by the gene is essential for the host cell to grow and survive in a selective medium. If the host cell is not transformed or transfected with a vector containing the gene, the host cell can not survive in a particular selective medium.
- Proteins encoded by a typical selection marker genes include proteins tolerant to an antibiotic or toxin, such as antibiotics or toxins including, for example ampicillin, kanamycin, tetracycline, neomycin, hygromycin, methotrexate and the like; proteins for compensating auxotroph for supplying critical nutrients not present in the culture medium, e.g., gene encoding D-alanine racemase.
- antibiotics or toxins including, for example ampicillin, kanamycin, tetracycline, neomycin, hygromycin, methotrexate and the like
- proteins for compensating auxotroph for supplying critical nutrients not present in the culture medium e.g., gene encoding D-alanine racemase.
- resistance-screening include transfection of an exogenous vector containing neomycin resistance gene, so that the host cell can survive in the medium containing neomycin, or G418.
- DHFR dihydrofolate reductase
- CHO Chinese Hamster Ovary
- the mammalian cell refers to a DHFR deficient cell, in which the gene of dihydrofolate reductase is not contained and nucleic acids can not be synthesized, therefore, it must be grown in a medium containing HT.
- a host cell is transfected using a vector, a positive clone containing an exogenous vector comprising both of target gene and DHFR gene can be obtained by selecting under the above culture conditions.
- the expression vector can further comprise other sequences, including signal peptide sequence, transcription termination sequence, enhancer sequence and the like.
- the vector of the present invention is a eukaryotic vector.
- the vector of the present invention is a pH vector for the eukaryotic expression of an antibody, which contains CMV promoter, internal ribosome entry site sequence (IRES), DHFR selection markers and other components.
- Methotrexate (MTX) is a DHFR inhibitor which can block the function of DHFR. When the cell culture medium contains MTX, DHFR is inhibited.
- the gene can be self-amplified by feedback regulation, so that genes at upstream and downstream will be amplified, therefore, target genes will be amplified, thereby increasing the expression of the target protein.
- the present invention relates to a vector comprising the host cell for expressing desired multifunctional antibody polypeptides.
- "Host cell” includes a single cell or a cell culture, which can receive and have received a vector comprising inserted polynucleotide.
- the host cell of the present invention may be any prokaryotic host cell or eukaryotic host cell.
- Eukaryotic host cells including yeast, insect cells, plant cells, mammalian cells may be preferred, since complex post-translational modification (e.g. glycosylation) of the target protein is present in a eukaryotic cell, and more and more of eukaryotic cells are used in large-scale cultivation.
- Common host cell lines include monkey kidney cells (COS-7 ATCC CRL 1651) , human embryonic kidney 293 cells and subcloned cell lines, baby hamster kidney cells (BHK, ATCC CCL10), Chinese hamster ovary (CHO) cells and the like.
- the eukaryotic host cell of the present invention is a Chinese hamster ovary cells.
- the present invention relates to a use of one or more of antibody polypeptides specifically recognizing precursor domain of pro-BDNF in preparation of a medicament to mitigate and / or inhibit chronic pain selected from the following group: chronic inflammatory pain, phantom limb pain, painful diabetic neuropathy, neuropathic pain, chronic lumbodorsalgia, chronic visceral pain, cancer pain, arthritis pain, craniofacial pain, trigeminal neuralgia, migraine, complex regional pain syndrome, and a combination thereof.
- chronic pain selected from the following group: chronic inflammatory pain, phantom limb pain, painful diabetic neuropathy, neuropathic pain, chronic lumbodorsalgia, chronic visceral pain, cancer pain, arthritis pain, craniofacial pain, trigeminal neuralgia, migraine, complex regional pain syndrome, and a combination thereof.
- the present invention also relates to a use of one or more of antibody polypeptide that specifically recognizes amino acids at positions 19-128 of precursor domain of pro-BDNF in preparation of a medicament to mitigate and / or inhibit acute or chronic pain selected from the following group: post-operative pain, acute inflammatory pain, chronic inflammatory pain, phantom limb pain, painful diabetic neuropathy, neuropathic pain, chronic lumbodorsalgia, chronic visceral pain, cancer pain, arthritis pain, craniofacial pain, trigeminal neuralgia, migraine, complex regional pain syndrome, and a combination thereof.
- acute or chronic pain selected from the following group: post-operative pain, acute inflammatory pain, chronic inflammatory pain, phantom limb pain, painful diabetic neuropathy, neuropathic pain, chronic lumbodorsalgia, chronic visceral pain, cancer pain, arthritis pain, craniofacial pain, trigeminal neuralgia, migraine, complex regional pain syndrome, and a combination thereof.
- the present invention further includes a pharmaceutical composition comprising said antibody polypeptides.
- the composition may also contain a pharmaceutically acceptable carrier.
- the pharmaceutical composition may be administered by conventional routes, including but not limited to, intravenous, intraperitoneal injection.
- the pharmaceutical composition of the invention may also be used in combination with other agents for inhibiting / preventing pain.
- the "effective amount" of the drug, compound or pharmaceutical composition of the present invention refers to an amount sufficient to produce advantageous and desired results, and the results include clinical outcomes of reducing or mitigating pain.
- An effective amount can be administered by one or several administrations.
- an effective amount means an amount sufficient to treat, reduce, decrease, and inhibit intensity of pain and / or prevent pain.
- an effective amount of the drug may be determined with or without another drug.
- "effective amount” may be considered to be under the conditions of administering one or more agents, or if desired results can be obtained or have been obtained when one single agent is administered in combination with one or more other agents, the single agent can be considered as being administered in an effective amount.
- Specific dosage should be determined according to factors, such as the route of administration, and patient's condition, which are within the skill of a skilled physician.
- PCR amplification was performed by using the following primers and cDNA of human tumor cell U87MG as template (commercially available from RAYGENE):
- the host strain BL21 (DE3) (commercially available from Novagen) for expression was transformed by pET22b-proBDNF plasmid, and plated on an ampicillin-resistant dish and invertion-cultured at 37 °C overnight. A single clone was picked for induced expression. After a single clone was picked, it was cultured with shaking to OD 600 0.6-0.8. Final concentration of 1 mM of IPTG was added at 30°C for 4 hrs, and bacteria liquid was collected.
- the precipitate was collected by centrifugation, 1/10 volumes of buffer A (50 mM NaH 2 PO 4 , 300 mM NaCl, 10 mM imidazole, pH 8.0) was added for resuspension, and PMSF was added (final concentration of 1 mM) and processed by ultrasound on ice (3 seconds of ultrasonic-process, 10 seconds of interval, 99 times for each cycle, 4 cycles), and centrifuged (4°C, 12000g) for 15 mins, and the supernatant was collected by centrifugation, and purified by affinity chromatography through Ni-NTA Agarose column (commercially available from QIAGEN) to obtain the expressed target protein.
- buffer A 50 mM NaH 2 PO 4 , 300 mM NaCl, 10 mM imidazole, pH 8.0
- PMSF was added (final concentration of 1 mM) and processed by ultrasound on ice (3 seconds of ultrasonic-process, 10 seconds of interval, 99 times for each cycle, 4 cycles), and centrifuge
- the solution was dialyzed against PBS, and then the purity of the purified protein after dialysis was analyzed through 12% SDS-PAGE, the content thereof is detected by A280, and a small quantity of sample was taken for detecting its molecular weight through SDS PAGE electrophoresis.
- the molecular weight of target bands in the first column is about 30 kD, which is substantially consistent with theoretical molecular weight of proBDNF, 27.8 kD.
- PCR amplification was performed by using the following primers and the plasmid pET22b-proBDNF obtained above as template:
- HEK293F cells Well-grown HEK293F cells (HEK293F, commercially available from LIFE) were seeded into a flask of cell culture at 1 ⁇ 10 6 Cells/ml, and incubated overnight at 37°C, 5% CO 2 120 rpm; V5F-pro-domain plasmid obtained in the above step and liposome (293Fectin, commercially available from LIFE) was diluted with DMEM and gently mixed, and incubated at room temperature for 20 mins. The incubated DNA-liposome complex was added into HEK293F cells, and incubated at 37°C, 5% CO 2 120 rpm for 72 hr.
- FLAG antibody affinity filler (ANTI-FLAG Agarose Affinity Gel, purchased from Sigma-Aldrich) was loaded on a column, FLAG affinity column was equilibrated with 5- 10 column volumes of lysis buffer (50 mM PB, 0.3M NaCl, 5% glycerol). Upon centrifugation, the supernatant of cell culture flowed through FLAG affinity column at 1 ml/min and the flow-through liquid was stored at 4°C.
- FLAG antibody affinity filler ANTI-FLAG Agarose Affinity Gel
- washing buffer 1 50 mM PB, pH 7.8, 0.3 M NaCl, 5% glycerol
- washing buffer 2 50 mM PB, pH 7.8, 0.5 M NaCl, 5% glycerol
- Example 3 Eukaryotic-expression of rat proBDNF pro-domain-Fc
- PCR amplification was performed by using the following primers and cDNA of rat as template (commercially available from RAYGENE):
- HEK293F cells Well-grown HEK293F cells (HEK293F, commercially available from LIFE) were seeded into a flask of cell culture at 1 ⁇ 10 6 Cells/ml, and incubated overnight at 37°C, 5% CO 2 120 rpm; V5F-cat-pro-domain plasmid obtained in the above step and liposome (293Fectin, commercially available from LIFE) was diluted with DMEM and gently mixed, and incubated at room temperature for 20 mins. The incubated DNA-liposome complex was added into HEK293F cells, and incubated at 37°C, 5% CO 2 120 rpm for 72 hr.
- the 1 ml of purified proBDNF protein (1.0 mg / mL) obtained in Example 1 as an antigen was completely emulsified and mixed with 1 mL of complete Freund's adjuvant (commercially available from by Sigma-Aldrich), and subcutaneously used to immunize 6-8 week-old BALB/c mice, 100 ⁇ g of human proBDNF antigen per mouse. After 4 weeks, human proBDNF antigen was emulsified and mixed with incomplete Freund's adjuvant, and used to immunize mice via intraperitoneal injection, per mouse. After an interval of 2 weeks, 50 ⁇ g of antigen was used for booster immunization via intraperitoneal injection.
- Example 2 1 week after the 4 th booster immunization, purified human proBDNF pro-domain obtained in Example 2 was used for coating, mouse anti-serum titer was detected by ELISA. Booster immunization was continued until mouse anti-serum titer > 10 5 . 3 weeks after the last booster immunization, 20 ⁇ g of human proBDNF pro-domain as said above was used for immunization in spleen and stored until use.
- Lymphocytes were isolated through a 100 mesh filter, fused with myeloma cell line SP2/0, and selectively cultured with hypoxanthine, aminopterin and thymidine (HAT) for 3 days. Afterwards, HT medium was supplemented, and cultured for another week.
- HAT hypoxanthine, aminopterin and thymidine
- Human proBDNF ahtigen of the above Examples of the present invention was used for coating, and positive clones were screened through ELISA, and subcloned for 3 times through limiting dilution, and cultured for another 2 months, and finally obtained a stable hybridoma cell line (each clone named as: 2B11, 2C7, 5C10, 4C3 , 6F3, 2F3, 8E1, 1G7).
- Colnes of hybridoma cells as said above were taken and used to intraperitoneally inject mice in each group at 5 ⁇ 10 5 cells / mouse for preparing ascites.
- 100 ml of ascites was taken, and diluted in 2 volumes of 0.06 M sodium acetate buffer pH 4.0.
- 4% octanoic acid was slowly added dropwise with stirring, and stirred for 30 mins.
- the obtained turbid liquid was centrifuged at 10000 g for 30 mins.
- the precipitate was discarded, and the supernatant was dialyzed overnight against 0.01 M phosphate buffer, pH 7.4.
- the dialysate was taken, and an equal volume of saturated ammonium sulfate was slowly added, and placed for 2 hours.
- the turbid liquid was centrifuged at 10000 g for 10 mins. The supernatant was discarded, and the precipitate was dissolved with 0.01 M PBS, pH 7.4. Upon dissolution, the solution was dialyzed against 0.01 M PBS, pH 7.4, during which the dialysis liquid was changed twice (the time interval for changing dialysis liquid shall not be less than 5 hours). The dialysate was centrifuged at 10000 g for 10 mins, the precipitate was discarded and the supernatant was collected.
- Protein G affinity column (purchased from GE) was used. The column was warmed to room temperature, and equilibrated with 5 column volumes of PBS (0.01 M PB, 0.15 M NaCl, pH 7.4). The collected supernatant as said above was loaded, and 5 column volumes of PBS was used for washing. The column was eluted by 0.1 M glycine-hydrochloric acid solution, pH 2.3 and the eluate was neutralized by 1/10 volume of 1 M disodium hydrogen phosphate solution, pH 9.0. The solution was dialyzed against 0.01 M PBS, pH 7.4, during which the dialysis liquid was changed twice (the time interval for changing dialysis liquid shall be more than 5 hours). The dialysate was centrifuged at 10000 g for 10 mins, the supernatant was filtered through a 0.22 um membrane and stored, thereby obtaining purified monoclonal antibody produced by each corresponding clone.
- Experiment group 1 purified human proBDNF protein obtained in Example 1 was diluted in PBS (0.01 M PB, 0.15 M NaCl, pH 7.4). There are 8 wells for each group corresponding to 8 purified monoclonal antibodies which will be subsequently added, respectively.
- Experiment group 2 purified human proBDNF pro-domain obtained in Example 2 was diluted in PBS (0.01 M PB, 0.15 M NaCl, pH 7.4). There are 8 wells for each group corresponding to 8 purified monoclonal antibodies which will be subsequently added, respectively.
- Experiment groups 1 and 2 50 ul (50 ng) of diluted protein was used for coating overnight at 4°C, respectively. Then the supernatant was discarded, each well was washed with PBS for 2 times, and blocked with PBS containing 5% milk powder at 37°C for 2 hours. And then, at 37°C, into 8 wells of Experiment groups 1 and 2 was added 50 ul (1 ug/ml) of 8 purified monoclonal antibodies obtained in Example 3.3, respectively for 1 hour. Each well was washed with PBST containing 0.5% Tween-20 for 3 times, and 50 ul of HRP labeled goat anti-mouse secondary antibody was added at 37°C for 1 hour.
- purified monoclonal antibodies 2B11 binds to human proBDNF and human proBDNF pro-domain, which demonstrates that the antibody 2B 11 binds to the common segment of both of the proteins, that is, the region of human proBDNF pro-domain.
- HRP horseradish peroxidase
- Experiment group 1 purified human proBDNF protein obtained in Example 1 was diluted in PBS (0.01 M PB, 0.15 M NaCl, pH 7.4).
- Experiment group 2 prokaryotically-expressed mouse proBDNF (purchased from Alomone labs) was diluted in PBS (0.01 M PB, 0.15 M NaCl, pH 7.4).
- Experiment group 3 rat proBDNF pro-domain eukaryotically-expressed in Example 3 was diluted in PBS (0.01 M PB, 0.15 M NaCl, pH 7.4). 50 ul (50 ng) of diluted protein in Expeiment group 1, 2 and 3 was used for coating overnight at 4°C, respectively. Then the supernatant was discarded, each well was washed with PBS for 2 times, and blocked with PBS containing 5% milk powder at 37°C for 2 hours. The supernatant was discarded, and 50 ul of diluted horseradish peroxidase-labeled 2B11 antibody of Example 4.5 (1 ug/ml) was added at 37°C for 1 hour.
- clone 2B11 binds to human proBDNF prepared in Example 1 and commercially purchased murine proBDNF as well as rat proBDNF pro-domain eukaryotically-expressed in Example 3.
- experiment groups were established according to the number of isotyping antibodies, wherein, in each group, 50 ul of diluted prokaryotically-expressed human proBDNF protein (50 ng) was added into each well for coating overnight at 4°C . The supernatant was discarded, each well was washed with PBS (0.01 M PB, 0.15 M NaCl, pH 7.4) for 2 times, and blocked with PBS containing 5% milk powder at 37°C for 2 hours. The supernatant was discarded, and 50 ul of diluted 2B11 antibody purified as above (1 ug/ml) was added into each well at 37 °C for 1 hour.
- the sequence of 2B11 was cloned by 5'-RACE method and confirmed by sequencing (details can be found in instructions of Takara 5'-full RACE Kit): 5' phosphate groups exposed in total RNA were dephosphorylated using alkaline phosphatase (CIAP). Total RNA was in an amount of 2 ug, and was recovered by phenol-chloroform extraction after reaction. 5' cap structure of mRNA was removed by using Tobacco Acid Pyrophosphatase (TAP), while remaining a phosphate group. 5' RACE Adaptor is connected to mRNA With T4 RNA ligase, and was recovered by phenol-chloroform extraction after reaction. Reverse transcription reaction was performed with reverse transcriptase, and used primers was Random 9 mers provided in Kit.
- TCP Tobacco Acid Pyrophosphatase
- the target gene was PCR-amplified by a high fidelity enzyme with the reverse transcription product as a template, and used primers were as follows:
- Nested PCR was performed with above-obtained PCR products as templates, and used primers were as follows:
- PCR products obtained above through amplification was purified and TA-cloning was performed (pGEM-T the Easy Vector Kit, commercially available from Promega, detailed method can be found in the instructions of the kit), thereby obtaining Teasy-2B11VH and Teasy-2B11V ⁇ vector respectively, which were sequenced to obtain heavy chain and light chain sequences of monoclonal antibodies 2B 11.
- Heavy chain and light chain sequences are shown in SEQ ID NO: 9 and SEQ ID NO: 10 respectively. According KabatMan, sequences of heavy chain variable region and light chain variable region can be determined as shown in SEQ ID NO: 7 and SEQ ID NO: 8.
- sequences of CDR1 , CDR2 , CDR3 in heavy chain variable region are shown in SEQ ID NO: 1-3 respectively, and sequences of CDR1 , CDR2 , CDR3 in light chain variable region are determined as shown in SEQ ID NO: 4-6 respectively.
- Example 6 Construction of chimeric antibody vectors pH-CH2B11 and pK-CH2B11 and preliminary identification of binding activities
- PCR amplification was performed using following primers with vector Teasy-2B11VH constructed in Example 5 of the present invention as a template,
- PCR amplification was performed with antibody vector pH-EGFRvIII (that is, pH-CH12, construction of which can be found in Example 7.1 of PCT/CN2009/074090 ),
- Products were recovered from agarose gel, dual-digested by NheI and Notl (commercially available from NEB), and connected to vector pH which was dual-digested by the same enzymes to obtain expression plasmid pH-CH2B11 containing chimeric 2B11 heavy chain, which was identified through PCR and confirmed through sequencing.
- PCR amplification was performed using following primers with Teasy-2B11V ⁇ constructed in Example 5 of the present invention as a template, 2BV ⁇ F (5'-cttgcattcttgttgctttggtttccaggtgcaagatgtgacatccagatgactc-3') (SEQ ID NO: 30), and 2BV ⁇ R (5'-agccaccgtacgttttatttccaactttg-3') (SEQ ID NO: 31), thereby obtaining light chain variable region of monoclonal antibody 2B11.
- Obtained amplified products were recovered from agarose gel, dual-digested by EcoRV and BsiWI (commercially available from NEB), and connected to vector pK which was dual-digested by the same enzymes to obtain expression plasmid pK-CH2B11 containing chimeric 2B11 light chain, which was identified through PCR and confirmed through sequencing.
- the expression vectors above constructed pH-CH2B11 and pK-CH2B11 were used to co-transfect CHO cells in suspension fro expression, and after 3 days, culture supernatant was collected. Expressed chimeric antibody CH2B 11 was contained in the supernatant of cultured CHO cells.
- the supernatant of cultured cells was taken for ELISA binding assay.
- the method was substantially identical with that in Example 4.4 of the present invention, except that only Experiment group 1 was included wherein human proBDNF prepared in Example 1 of the present invention was used for coating, and in each well, serial dilutions of cell supernatant of this Example were added instead of clones of corresponding 8 monoclonal antibodies. Similarly, when the absorbance value is greater than the reading in the negative control well by three times, it was identified as positive.
- Experiment results are shown in FIG. 7 , for chimeric antibody CH2B1, the supernatant of cultured CHO cells in a dilution of 1:32 still exhibited binding activity to human proBDNF.
- SD rats (weighing 200-250 g) were divided into 2B11 group and control group (in this experiment, the same volume of PBS was used as a control group).
- Modeling was mainly established by injecting 50 ul of 1% formalin into planta pedis of a mouse. At 0.5 hours before modeling, 2B11 (75 ⁇ g/kg) or placebo in an equal amount was injected via tail vein.
- Administration via tail vein was performed as follows: tail of a rat was washed with warm water, the site for injection was disinfected by using iodine complex, and 1 ML sterile syringe loaded with an injection dosage of antibody was used to puncture the tail vein at an angle about 10 degree parallel to the tail with slightly negative pressure.
- 2B11 was injected in a concentration of 500 ug/kg and a total amount of 300 ⁇ L.
- Modeling method of formalin inflammatory pain can be mainly found in Bellasio S et al., that is, a mouse is firstly placed in a transparent Plexiglas box (30 ⁇ 20 ⁇ 20 cm) for adapting for 30 mins, and afterwards, 50 ul of 1% formalin solution is injected into planta of its right hind foot via subcutaneous injection. Upon injection, the mouse is immediately placed back into the box, the time of the mouse licking and biting the injected foot was recorded for 1 hour with 5 mins as time interval.
- Subcutaneous injection of formalin in plantar is a classic model of acute inflammatory pain, and in the model, there will be a special animal spontaneous pain behavior, that is, licking and biting foot. And the longer the time of licking or biting foot, the higher the intensity of pain.
- spontaneous pain behavior can generally be divided into two phases, the first phase appears at 0-5 mins after injection, the second phase appears at 15-60 mins after injection, and there will be an intermittent period between the two phases, wherein the second phase is considered as being relevant to pain sensitization (central sensitization) mechanism.
- the present experiment observes effects of 2B 11 on CFA-induced chronic inflammatory pain. Pain induced by plantar injection of CFA is a classic model of chronic inflammatory pain, which is of long duration. Upon plantar injection of CFA, mechanical pain threshold of the rats is reduced for over 3 weeks.
- Von Frey filaments method was employed to observe Paw Withdrawal Threshold (PWT).
- Von frey filament was designed in 1896 by Maximilian von Frey, which is a tactile measuring device. Contacting wires were made of nylon filaments of different diameters, and when using these filaments, they come into contact with the skin (or other sites to be tested, such as planta of an animal) and the filaments were bent to form S-shape by applying a force. Since the strength for bending the filaments can be considered as being continuous, these filaments can accurately reflect the strength applied to the area to be measured.
- Von frey filament is one of the most commonly used tools for measuring all kinds of post-pain mechanical hyperalgesia.
- the minimal sequence composition can be 4 times, such as "XXXX", wherein stimulus of rats occurred in a range of 2.0-0.6 g were positive; or can be 6 times, wherein stimulus occurred in a range of 2.0-0.6 g were negative.
- Cutting pain model of rat hind paws is the most commonly used animal model for surgical pain. After cutting at hind paws, rats elevate the cut limb, can not bear weight, while lick the paw. Therefore, pain score is often used to elevate the degree of cutting pain. Rats were observed for grounding situation, every 5 minutes (generally calculated in hours). If the hind paw was always elevated, it will be given 2 points; if the rat can ground, but can not bear weight (whether the mesh of the cage is deformed is used as a criterion), it will be given 1 point; and if the rat can completely ground and bear weight, it will be given 0 point. The higher the score, the stronger the degree of pain.
- CPS Cumulative Pain Score
- Experiment grouping is the same as Example 8.1. At 15 minutes before the operation, 500 ug/kg of 2B11 was given via intravenous injection. Rats were observed for pain score ( Fig. 10 and following table 4) and mechanical pain threshold of hind paw ( Figure 11 and following table 5) at different time periods after operation, and it can be found that: In 2B 11 experiment group, pain scores of mouse measured at 1 hour after the cutting operation were significantly lower compared with the mouse in the control group, wherein the difference at 3 hour after the cutting operation was the most significant. And pain scores measured at 6 hour after the cutting operation were still significantly lower than those of the control group.
- mice Upon intraperitoneal injection of acetic acid, mice mainly exhibit writhing responses, such as abdominal contraction, stretching (Writhing Test), especially at 1 hour after injection. Observation of writhing responses during 1 hour after the injection of acetic acid is a commonly used model for screening analgesics. Intraperitoneal injection of 0.6% acetic acid (0.2 ml) per mouse will cause chemical visceral pain.
- Experiment grouping is the same as Example 8.1.
- monoclonal antibody 2B11 500 ug/kg, 0.2 ml
- placebo in the same volume
- FIG. 12 and corresponding data in the following table 6 it is shown that, compared with the mice in the control group, writhing responses of the mice in 2B 11 group are significantly reduced, which demonstrates that pre-treatment of monoclonal antibody 2B11 of the present invention can reduce visceral pain induced by intraperitoneal injection of acetic acid.
- Table 6 Writhing response in control group (time/hour) Writhing response in 2B11 group (times/hour) 117 74 78 58 90 57 95 47 137 62 89 53 101 22 Means 101 53 . 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
- The present invention relates to preparation of a monoclonal antibody against human brain-derived neurotrophic factor precursor protein (proBDNF) and uses of such monoclonal antibody to mitigate and / or inhibit various types of acute and chronic pain, such as post-operative pain, acute inflammatory pain, chronic inflammatory pain, phantom limb pain, painful diabetic neuropathy, neuropathic pain, chronic lumbodorsalgia, chronic visceral pain, cancer pain, arthritis pain, craniofacial pain, trigeminal neuralgia, migraine, complex regional pain syndrome, and the likes.
- Pain is the fifth vital signs besides body temperature, respiration, heart rate, blood pressure, which can serve as a warning when the body is hurt and cause a series of defensive responses of the body. However, excessive pain will cause damage to the body, and become one kind of unbearable torture to the body. Therefore, analgesia is an important task for healthcare practitioners. Chronic pain threatens the survival and quality of human life, and also causes a great burden on families and society. According to American Pain Society, it was reported that the prevalence of chronic pain in United States was estimated as 35.5%, including 105 million people. It costs over $ 100 billion, directly resulting in the consumption of healthcare spending and the loss of working hours.
- The most commonly used analgesics include acetaminophen, non-steroidal anti-inflammatory drugs and opioid receptor agonists, such as tramadol and morphine. Non-steroidal anti-inflammatory drugs (NSAIDs) have weak analgesic efficacy, and may lead to gastrointestinal bleeding, renal failure and liver dysfunction as well as other side effects; and overdose of opioids will cause respiratory depression, and long-term use thereof will lead to side effects, such as constipation, abuse, dependence and addiction. In recent years, there are some other analgesics which are also marketed, for example antidepressants (such as Duloxetine, Lilly), anticonvulsants (such as Puri Galindo, Lyrica™, Pfizer) and selective cyclooxygenase-2 (COX-2) inhibitors (such as Parecoxib, Pfizer).
- A new mode for developing analgesic drugs is the mechanism-mediated development of new drug targets. For such mode, the mechanism of pain is mainly studied to find an important factor or target for regulating occurrence and development of pain, thereby developing a new medicament to intervene with the factor or target and achieve analgesia. Many clinical applications based on the results of such basic research are currently tested, however, few of them are successful.
- One typical example is the development of anti-nerve growth factor (Nerve Growth Factor, NGF) antibodies. NGF is a member from neurotrophic factor family, and plays an important role in the survival and apoptosis of neuron during development. Basic research shows that NGF may promote pain, therefore blocking NGF may be an important method for treating pain. Therefore many anti-NGF antibodies were developed, including Tanezumab (Pfizer), SAR164877/REGN475 (Sanofi /Regeneron) and NJ-42160443/AMG403 (Johnson & Johnson / Amgen). These drugs show analgesic effects in animal models and clinical trials of phase I / II also show safety and analgesic effects, however, in the clinical trial of phase III in rheumatoid arthritis and ankylosing spondylitis patients for evaluating clinical efficacy and safety of analgesia of anti-NGF antibodies in combination with NSAID drugs, painless ischemic necrosis of caput femoris can be found in a small number of patients (Garber K Painkiller Novel Fate of the mAbs Hangs in Balance. Nat Biotechnol 2011, 173-174; Seidel M, Lane N, Control of Arthritis Pain with Anti-Nerve-Growth Factor, Risk and Benefit, Curr Rheumatol Rep, 2012, 583-585).
- Therefore, there is a huge market demand in the development of analgesics with new mechanism.
- Brain-derived neurotrophic factor BDNF is a neurotrophic factor discovered after nerve growth factor was discovered, molecular weight of which is 12.4 kDa. BNDF mainly distributes in central nervous system, and is also synthesized in peripheral nervous system and plays an important role in the regulation of survival, differentiation of neuron and synaptic plasticity and damage repair. Currently, there is an evidence to show that BDNF is not only an important factor in regulating development of nervous system and emotional disorders, but also an important mediator of pain. Precursor for brain-derived neurotrophic factor (proBDNF) is synthesized in endoplasmic reticulum from BDNF gene through transcription and translation. The peptide chain is of 247 amino acids in length, and the theoretical molecular weight of the amino acid sequence is 27.8 KD. However, the molecular weight may be varied in a range of 32-36 kD due to different degree of glycosylation for the protein. In ProBDNF, the amino acid sequence at 1-18 positions is signal peptide sequence, and two fragments are produced during secretion process, wherein one fragment is a polypeptide fragment containing amino acids at 19-129 positions (that is, precursor domain), which is called precursor domain (proBDNF pro-domain), and another fragment is a fragment of amino acids at 130-247 positions (that is, mature domain), which will form BDNF with bioactivities upon processing.
- At present, a lot of evidence shows that proBDNF is not only an intermediate of mature BDNF, but also can be used as a ligand to bind high-affinity receptor, p75 neurotrophin receptor (p75NTR) for exerting biological effects. Currently, the function of proB DNF-p75NTR signaling pathway in pain is unclear, however, there is a point-of-view that spinal sensitization mechanism of pain is similar to forming mechanism of Long-term potentiation (LTP) / long term depression (LTD) of hippocampus, while BDNF-TrkB and proBDNF-p75NTR signaling pathway are important signaling molecules for regulating LTP / LTD.
- In 2012, experiments from Zhang, Yanling (Central South University) demonstrated that the expression of proBDNF in dorsal root ganglion was up-regulated after hind legs of a rat were cut; after an adenoviral vector of proBDNF was injected into hind legs of a rat, a great deal of proBDNF was expressed on nerve fibers by the adenovirus vector, and over-expression of proBDNF caused a significant decrease in withdrawal threshold of hind legs to mechanical stimulation and inflammation in plantar tissue; and withdrawal threshold of hind legs after the hind legs of a rat were cut can be increased by intraperitoneal administration of anti-proBDNF polyclonal antibody. Cutting pain belongs to acute pain. For acute and chronic pain, both of outer peripheral sensitization and central sensitization can occur, and the difference between which is that: for outer peripheral sensitization, transmitters released by nerve fibers or axons in local tissue and intracellular signaling pathways are different, and pain transmitter and signaling pathways associated with dorsal root ganglion are also different, the latter of which lasts longer; in addition, for central sensitization, sustained activation of glial cells in spinal cord may also be the most important difference between the mechanisms of acute and chronic pain.
- In one aspect, the present invention relates to an antibody polypeptide that specifically recognizes amino acids at positions 19-128 of precursor domain of protein (pro-BDNF pro-domain), including a heavy chain variable region comprising the following amino acid sequence: (a) CDR1 region of SEQ ID NO: 1, CDR2 region of SEQ ID NO: 2, (c) CDR3 region of SEQ ID NO: 3; and / or a light chain variable region comprising the following amino acid sequence: (d) CDR1 region of SEQ ID NO: 4, (e) CDR2 region of SEQ ID NO: 5, (f) CDR3 region of SEQ ID NO: 6.
- In a specific embodiment, the antibody polypeptide is a monoclonal antibody. In a more specific embodiment, in the antibody polypeptide, the amino acid sequence of heavy chain variable region is SEQ ID NO: 7, and the amino acid sequences of light chain variable region is SEQ ID NO: 8. In another specific embodiment, in the antibody polypeptide, the amino acid sequence of heavy chain is SEQ ID NO: 9, and the amino acid sequence of light chain is SEQ ID NO: 10. In another particular embodiment, the antibody polypeptide may be selected from a humanized antibody polypeptide, a chimeric antibody polypeptide, an affinity maturated antibody polypeptide or one or more combinations thereof. In another particular embodiment, the antibody polypeptide is an antibody polypeptide competing with the antibody polypeptides as said above.
- In another aspect, the present invention relates to a nucleic acid sequence encoding the antibody polypeptides as said above. In a specific embodiment, the nucleic acid encoding the amino acid sequence of heavy chain variable region of the antibody polypeptide is SEQ ID NO: 11, and the nucleic acid encoding the amino acid sequence of light chain variable region of the antibody polypeptide is SEQ ID NO: 12. In another specific embodiment, the nucleic acid encoding the amino acid sequence of heavy chain of the antibody polypeptide is SEQ ID NO: 13, and the nucleic acid encoding the amino acid sequence of light chain of the antibody polypeptide is SEQ ID NO: 14.
- In another aspect, the present invention relates to a vector comprising the nucleic acid sequence.
- In another aspect, the present invention relates to a host comprising the vector.
- In another aspect, the present invention relates to a use of one or more of antibody polypeptides specifically recognizing precursor domain of pro-BDNF in preparation of a medicament to mitigate and / or inhibit chronic pain selected from the following group: chronic inflammatory pain, phantom limb pain, painful diabetic neuropathy, neuropathic pain, chronic lumbodorsalgia, chronic visceral pain, cancer pain, arthritis pain, craniofacial pain, trigeminal neuralgia, migraine, complex regional pain syndrome, and a combination thereof.
- In another aspect, the present invention relates to a use of the antibody polypeptide in preparation of a medicament to mitigate and / or inhibit pain selected from the following group: post-operative pain, acute inflammatory pain, chronic inflammatory pain, phantom limb pain, painful diabetic neuropathy, neuropathic pain, chronic lumbodorsalgia, chronic visceral pain, cancer pain, arthritis pain, craniofacial pain, trigeminal neuralgia, migraine, complex regional pain syndrome, and a combination thereof.
- In another aspect, the present invention relates to a pharmaceutical composition comprising an effective amount of the antibody polypeptide. In a specific embodiment, the pharmaceutical composition is administered by intravenous or intraperitoneal injection.
- The antibody polypeptide and the corresponding pharmaceutical composition of the present invention are capable of specifically recognizing the precursor domain of proBDNF (pro-domain), inhibiting and / or preventing various types of acute pain or chronic pain, for example, post-operative pain, acute inflammatory pain, chronic inflammatory pain, phantom limb pain, painful diabetic neuropathy, neuropathic pain, chronic lumbodorsalgia, chronic visceral pain, cancer pain, arthritis pain, craniofacial pain, trigeminal neuralgia, migraine, complex regional pain syndrome, and a combination thereof. The antibody polypeptide and the corresponding pharmaceutical composition of the present invention can produce technical effects which can not be achieved in the prior art, and possess broad and good prospects for clinical application.
-
-
Figure 1 shows results of SDS-PAGE electrophoresis of purified human proBDNF protein expressed in host strain BL21 (DE3) according to Example 1 of the present invention. 1, purified human proBDNF protein; 2, Protein Molecular Weight Marker (Low), commercially available from TAKARA (Item: 3450). -
Figure 2 shows results of SDS-PAGE electrophoresis of purified precursor domain of human proBDNF expressed in HEK293F cell according to Example 2 of the present invention. 1, purified precursor domain of human proBDNF; 2, Protein Molecular Weight Marker (Low), commercially available from TAKARA (Item: 3450). -
Figure 3 shows results of SDS-PAGE electrophoresis of purified fused protein of precursor domain of rat proBDNF expressed in HEK293F cell according to Example 3 of the present invention. 1, purified fused protein of precursor domain of rat proBDNF; 2, Protein Molecular Weight Marker (Low), commercially available from TAKARA (Item: 3450). -
Figure 4 shows experimental results of specific antigen binding region of anti-proBDNF monoclonal antibody produced by hybridoma cell lines in Example 3 of the present invention against human proBDNF and human proBDNF precursor domain. -
Figure 5 shows experimental results of specific antigen binding region of anti-proBDNF monoclonal antibody 2B 11 in Example 4 of the present invention against human proBDNF precursor domain, rat proBDNF precursor domain and mouse proBDNF. -
Figure 6 shows results of subtype analysis on anti-proBDNF monoclonal antibody 2B11 according to Example 3 of the present invention. -
Figure 7 shows the experimental results of binding activity of human-mouse chimeric antibody CH2B 11 in Example 6 of the present invention and human proBDNF protein in Example 1 of the present invention under different diluting conditions. -
Figure 8 shows, compared with blank control, effects of 2B11 injected via tail vein on biphasic pain induced by formalin and represented by licking time of SD rat. -
Figure 9 shows, compared with blank control, effects of 2B11 injected via tail vein on chronic persistent inflammatory pain induced by plantar injection of CFA. -
Figure 10 shows, compared with blank control, effects of 2B11 injected via tail vein on pain score of cutting pain of a rat's hinder legs. -
Figure 11 shows, compared with blank control, effects of 2B11 injected via tail vein on area of mechanical pain of cutting pain of a rat's hinder legs. -
Figure 12 shows, compared with blank control, effects of 2B11 intraperitoneally injected on writhing response induced by acetic acid in a mouse. - The anti-proBDNF antibody polypeptide of the present invention can specifically recognizes amino acids at positions 19-128 of precursor domain of pro-BDNF (pro-domain), including a heavy chain variable region comprising the following amino acid sequence: (a) CDR1 region of SEQ ID NO: 1, CDR2 region of SEQ ID NO: 2, (c) CDR3 region of SEQ ID NO: 3; and / or light chain variable region comprising the following amino acid sequence: (d) CDR1 region of SEQ ID NO: 4, (e) CDR2 region of SEQ ID NO: 5, (f) CDR3 region of SEQ ID NO: 6. In each experiment for evaluating pain, mice treated by the antibody, compared with mice in the group of blank control, exhibit significant pain-inhibiting and preventing effects. The antibody polypeptides of the present invention not only inhibit and / or prevent various types of acute pain or chronic pain, for example, post-operative pain, acute inflammatory pain, chronic inflammatory pain, phantom limb pain, painful diabetic neuropathy, neuropathic pain, chronic lumbodorsalgia, chronic visceral pain, cancer pain, arthritis pain, craniofacial pain, trigeminal neuralgia, migraine, complex regional pain syndrome, and a combination thereof.
- "Antibody polypeptide" of the present invention refers to an immunoglobulin molecule, which can specifically recognize target sites, such as polysaccharides, polynucleotides, lipids, polypeptides and the likes, through at least one antigen recognition site in the variable region of the immunoglobulin. As used herein, the term "antibody polypeptide" includes intact polyclonal antibodies and monoclonal antibodies, and also includes fragments thereof, e.g., single chain antibody (scFV), Fd fragment, Fab fragment, F(ab')2 fragment, single domain antibody fragment, isolated CDR fragment and derivatives thereof, such as mutants thereof, or immunoglobulin molecule structure comprising modification of at least one antigen binding site.
- An intact antibody consists of two identical heavy chains and two identical light chains, each of which contains one variable region (V region) and one or more constant region (C region). The variable region is responsible for binding to an antigen, and the constant region is primarily responsible for binding an effector. In each variable region, there are three flexible rings with highly diversity, called complementary determining region (CDR), which are primarily responsible for antigen-recognition. Other parts of the variable region comprise rigid β sheet and support so-called framework regions (FRs). CDR and FR are spaced to form a sandwich structure.
- "Single-chain antibody (scFV) fragment" refers to an antibody fragment constructed by gene engineering, which is a recombinant protein comprising a heavy chain variable region (VH) connecting to a light chain variable region (VL) via a linker, and the two domains are associated via the linker to form an antigen binding site. The size of a scFV is generally 1/6 of a complete antibody.
- "Fd fragment" refers to an antibody fragment consisting of heavy chain VH and CH1.
- "Fab fragment" refers to a heterodimer consisting of a Fd fragment (consisting of heavy chain VH and CH1) and an entire light chain formed via inter-chain disulfide bonds. The size of "Fab antibody" is 1/3 of an intact antibody, which only contains one antigen binding site.
- "F(ab')2 fragment" refers to a bivalent fragment comprising two linked Fab fragments.
- "Single domain antibody" consists of a heavy chain variable region or light chain variable region. The antibody fragment is so named since it only consists of one domain. The size of the fragment is 1/12 of an intact antibody.
- "Derivatives" include, for example, derivatives of the antibody obtaining by phage display techniques. Efficiency of phage antibodies binding EGFR or CD3 antigen epitope can be increased by, for example, surface plasmon resonance technology used in BIAcore system (Schier , human antibody hybridomas 7 (1996), 97-105; Malmborg , Immunol. Methods., 183 (1995), 7-13). The method also includes, for example, the preparation method for chimeric antibodies disclosed in
WO 89/09622 EP-A10239400 andWO90/07861 WO91/10741 WO94/02602 WO96/33735 - The antibody or fragments thereof used in the present invention may be further modified by one of the conventional techniques known in the art or combinations thereof, for example, deletions, insertions, substitutions, additions of amino acids, and / or recombination, and / or other modification methods. The method for introducing such modification into DNA sequence of an antibody according to the amino acid sequence thereof is well known to a skilled person.
- The antibody or antibody fragment of the present invention may be humanized, chimeric or murine antibody. As used herein, "humanized antibody" refers to an antibody having an amino acid sequence corresponding to an antibody produced by human, and / or an antibody prepared by techniques for preparing humanized antibody known in the art and disclosed in the present application. Humanized antibody mainly refers to an antibody from a murine (or other non-human) monoclonal antibody, wherein the murine (or other non-human) monoclonal antibody is modified and re-expressed through gene clone, DNA recombination, and most of amino acid sequence of the murine (or other non-human) monoclonal antibody is replaced by a human sequence. And the humanized antibody can substantially maintain the affinity and specificity of the parent murine monoclonal antibody, and also possess reduced heterogenicity, therefore, it is favorable to be applied in human. Humanized antibodies include chimeric antibodies, modified antibody (also named as CDR grafting antibody), surface re-shaped antibodies or fully humanized antibodies. Humanized antibodies may also be produced by a variety of methods known in the art. For example, a humanized antibody can be selected from a phage library expressing humanized antibodies. Humanized antibodies can also be prepared by introducing human immunoglobulin loci in transgenic animals. The transgenic animal can be, for example, a mouse, genes of endogenous immunoglobulin of which have been partially or completely inactivated. Furthermore, humanized antibodies may also be prepared by immortalizing human B lymphocytes producing antibodies against a specific antigen.
- "Chimeric antibody" refers to an antibody, wherein a portion of the amino acid sequence of heavy chain and light chain is homologous to the corresponding sequence of an antibody from a particular species, while other portions of the chain is homologous to the corresponding sequence from another particular species. Typically, in a chimeric antibody, heavy chain and light chain variable regions are similar to variable regions of a mammalian species, while the constant regions are homologous to the sequence from another mammalian species. Advantages of chimeric antibody are that it can be prepared by combining variable regions which can be easily prepared from origins known in the art by using currently available lymphoma cells or B cells of non-human host, and constant regions obtained from, for example a preparation of human cells. The specificity of the chimeric antibody is not affected by its origin, since the constant region thereof is human origin and is not likely to cause immune response in a human recipient. Of course, the definition of chimeric antibody is not limited to the specific examples described herein.
- Modified antibody is also named as CDR grafting antibody, wherein CDR in variable region of an antibody is the region of the antibody to recognize and bind antigen and directly determine the specificity of the antibody. CDR of a murine monoclonal antibody is grafted to variable region of a human antibody to replace CDR of the human antibody, therefore, the obtained human antibody will possess antigen-binding specificity of the murine monoclonal antibody and reduced heterogenicity. However, although an antigen mainly contacts with CDR of an antibody, FR region will generally be involved, thereby influencing spatial configuration of CDR. Therefore, after FR region is changed to human FR region, configuration of CDR of the original monoclonal antibody may be altered due to V region formed by such interchimeric murine CDR and human FR, and capability of binding an antigen will be reduced or even significantly reduced. Currently, an antibody can be designed at molecular level, certain key residues in murine FR region can be introduced into human FR region, and if properly configured, affinity of the obtained antibody is comparable with that of the original murine antibody.
surface re-shaped antibody refers to an antibody obtained from humanized modification to surface amino acid residues of a heterologous antibody. Principles of the method are that only regions which are significantly different from those in a human antibody will be replaced, and amino acids which are similar to surface residues of a human antibody are selected for replacement, thereby maintaining activities of an antibody and reducing heterogenicity. Additionally, the replaced segments should not be excessive, and residues which will influence the size of side chain, charge, hydrophobicity, or may form hydrogen bonds thus affecting conformation of complementary determining region (CDR) of an antibody shall not be replaced. - Fully humanized antibody refers to such antibody, which is obtained by transferring an antibody-encoding gene of human into a genetically engineered antibody gene-deleted animal through transgenic or chromosome transfer technology, and the animal expresses human antibodies, thereby obtaining fully humanized antibodies.
- As used herein, the term "competition" means that an antibody polypeptide exhibits immunological competitiveness in in vitro experiments, and immunoassay and conditions thereof for immunological competitiveness are well known in the art. An antibody polypeptide competing with the antibody polypeptide of the present invention may include, for example, an antibody polypeptide with similar and / or identical antigen-binding properties obtained by conservatively replacing one or more amino acids in CDR regions (CDR1, CDR2, CDR3) of heavy chain and / or light chain variable region of an antibody polypeptide or one or more amino acids in frame regions of an antibody polypeptide through genetic engineering methods known in the art.
- In another aspect, the present invention relates to a vector comprising a nucleotide sequence encoding the above polypeptide. The vector can be an eukaryotic vector or a prokaryotic vector, as long as the vector satisfies the following requirements: (a) coding sequence of the vector contains the sequence for replication initiation, so that the vector can be replicated in a host cell, (b) the vector comprises a gene sequence encoding a selectable marker, and the protein encoded by the gene is essential for the host cell to grow and survive in a selective medium. If the host cell is not transformed or transfected with a vector containing the gene, the host cell can not survive in a particular selective medium. Proteins encoded by a typical selection marker genes include proteins tolerant to an antibiotic or toxin, such as antibiotics or toxins including, for example ampicillin, kanamycin, tetracycline, neomycin, hygromycin, methotrexate and the like; proteins for compensating auxotroph for supplying critical nutrients not present in the culture medium, e.g., gene encoding D-alanine racemase. Examples of resistance-screening include transfection of an exogenous vector containing neomycin resistance gene, so that the host cell can survive in the medium containing neomycin, or G418. Another example is using dihydrofolate reductase (DHFR) selectable marker in a mammalian cell, such as Chinese Hamster Ovary (CHO) cell. The mammalian cell refers to a DHFR deficient cell, in which the gene of dihydrofolate reductase is not contained and nucleic acids can not be synthesized, therefore, it must be grown in a medium containing HT. When a host cell is transfected using a vector, a positive clone containing an exogenous vector comprising both of target gene and DHFR gene can be obtained by selecting under the above culture conditions. (c) the coding sequence of the vector comprises a promoter sequence, (d) the expression vector can further comprise other sequences, including signal peptide sequence, transcription termination sequence, enhancer sequence and the like. Preferably, the vector of the present invention is a eukaryotic vector. Preferably, the vector of the present invention is a pH vector for the eukaryotic expression of an antibody, which contains CMV promoter, internal ribosome entry site sequence (IRES), DHFR selection markers and other components. Methotrexate (MTX) is a DHFR inhibitor which can block the function of DHFR. When the cell culture medium contains MTX, DHFR is inhibited. The gene can be self-amplified by feedback regulation, so that genes at upstream and downstream will be amplified, therefore, target genes will be amplified, thereby increasing the expression of the target protein.
- In another aspect, the present invention relates to a vector comprising the host cell for expressing desired multifunctional antibody polypeptides. "Host cell" includes a single cell or a cell culture, which can receive and have received a vector comprising inserted polynucleotide.
- According to used vectors, the host cell of the present invention may be any prokaryotic host cell or eukaryotic host cell. Eukaryotic host cells, including yeast, insect cells, plant cells, mammalian cells may be preferred, since complex post-translational modification (e.g. glycosylation) of the target protein is present in a eukaryotic cell, and more and more of eukaryotic cells are used in large-scale cultivation. Common host cell lines include monkey kidney cells (COS-7 ATCC CRL 1651) , human embryonic kidney 293 cells and subcloned cell lines, baby hamster kidney cells (BHK, ATCC CCL10), Chinese hamster ovary (CHO) cells and the like. Preferably, the eukaryotic host cell of the present invention is a Chinese hamster ovary cells.
- The present invention relates to a use of one or more of antibody polypeptides specifically recognizing precursor domain of pro-BDNF in preparation of a medicament to mitigate and / or inhibit chronic pain selected from the following group: chronic inflammatory pain, phantom limb pain, painful diabetic neuropathy, neuropathic pain, chronic lumbodorsalgia, chronic visceral pain, cancer pain, arthritis pain, craniofacial pain, trigeminal neuralgia, migraine, complex regional pain syndrome, and a combination thereof.
- The present invention also relates to a use of one or more of antibody polypeptide that specifically recognizes amino acids at positions 19-128 of precursor domain of pro-BDNF in preparation of a medicament to mitigate and / or inhibit acute or chronic pain selected from the following group: post-operative pain, acute inflammatory pain, chronic inflammatory pain, phantom limb pain, painful diabetic neuropathy, neuropathic pain, chronic lumbodorsalgia, chronic visceral pain, cancer pain, arthritis pain, craniofacial pain, trigeminal neuralgia, migraine, complex regional pain syndrome, and a combination thereof.
- The present invention further includes a pharmaceutical composition comprising said antibody polypeptides. The composition may also contain a pharmaceutically acceptable carrier. The pharmaceutical composition may be administered by conventional routes, including but not limited to, intravenous, intraperitoneal injection. The pharmaceutical composition of the invention may also be used in combination with other agents for inhibiting / preventing pain.
- The "effective amount" of the drug, compound or pharmaceutical composition of the present invention refers to an amount sufficient to produce advantageous and desired results, and the results include clinical outcomes of reducing or mitigating pain. An effective amount can be administered by one or several administrations. For the purposes of the present invention, an effective amount means an amount sufficient to treat, reduce, decrease, and inhibit intensity of pain and / or prevent pain. As appreciated under clinical conditions, an effective amount of the drug may be determined with or without another drug. Thus, "effective amount" may be considered to be under the conditions of administering one or more agents, or if desired results can be obtained or have been obtained when one single agent is administered in combination with one or more other agents, the single agent can be considered as being administered in an effective amount. Specific dosage should be determined according to factors, such as the route of administration, and patient's condition, which are within the skill of a skilled physician.
- The invention will be further illustrated with reference to the following specific examples. It is to be understood that these examples are only intended to illustrate the invention, but not to limit the scope of the invention. For the experimental methods in the following examples without particular conditions, they are performed under routine conditions, such as conditions described in Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Laboratory Press, 1989, or as instructed by the manufacturer.
- PCR amplification was performed by using the following primers and cDNA of human tumor cell U87MG as template (commercially available from RAYGENE):
- PROBDNF-F: 5' GCGAATTCCCCATGAAAGAAGCAAACATCC 3' (SEQ ID No: 15)
- PROBDNF-R: 5' CCGCTCGAGTTATCTTCCCCTTTTAATGGTCAATG 3' (SEQ ID No: 16)
- The host strain BL21 (DE3) (commercially available from Novagen) for expression was transformed by pET22b-proBDNF plasmid, and plated on an ampicillin-resistant dish and invertion-cultured at 37 °C overnight. A single clone was picked for induced expression. After a single clone was picked, it was cultured with shaking to OD600 0.6-0.8. Final concentration of 1 mM of IPTG was added at 30°C for 4 hrs, and bacteria liquid was collected. The precipitate was collected by centrifugation, 1/10 volumes of buffer A (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0) was added for resuspension, and PMSF was added (final concentration of 1 mM) and processed by ultrasound on ice (3 seconds of ultrasonic-process, 10 seconds of interval, 99 times for each cycle, 4 cycles), and centrifuged (4°C, 12000g) for 15 mins, and the supernatant was collected by centrifugation, and purified by affinity chromatography through Ni-NTA Agarose column (commercially available from QIAGEN) to obtain the expressed target protein. The solution was dialyzed against PBS, and then the purity of the purified protein after dialysis was analyzed through 12% SDS-PAGE, the content thereof is detected by A280, and a small quantity of sample was taken for detecting its molecular weight through SDS PAGE electrophoresis. According to results of SDS-PAGE shown in
Fig. 1 , the molecular weight of target bands in the first column is about 30 kD, which is substantially consistent with theoretical molecular weight of proBDNF, 27.8 kD. - PCR amplification was performed by using the following primers and the plasmid pET22b-proBDNF obtained above as template:
- BDNFproVF1 5'GCTGGCTAGCACCCATGAAAGAAGCAAACATCCGAG3' (SEQ ID NO: 17)
- BDNFproVR1 5'CCGCTCGAGGTGGCGCCGGACCCTCATG 3' (SEQ ID NO: 18)
- Well-grown HEK293F cells (HEK293F, commercially available from LIFE) were seeded into a flask of cell culture at 1 × 106 Cells/ml, and incubated overnight at 37°C, 5% CO2 120 rpm; V5F-pro-domain plasmid obtained in the above step and liposome (293Fectin, commercially available from LIFE) was diluted with DMEM and gently mixed, and incubated at room temperature for 20 mins. The incubated DNA-liposome complex was added into HEK293F cells, and incubated at 37°C, 5% CO2 120 rpm for 72 hr. Cell culture fluid was collected and centrifuged at 4500 g for 15 mins, the supernatant was taken and cells were discarded. 1 ml of FLAG antibody affinity filler (ANTI-FLAG Agarose Affinity Gel, purchased from Sigma-Aldrich) was loaded on a column, FLAG affinity column was equilibrated with 5- 10 column volumes of lysis buffer (50 mM PB, 0.3M NaCl, 5% glycerol). Upon centrifugation, the supernatant of cell culture flowed through FLAG affinity column at 1 ml/min and the flow-through liquid was stored at 4°C. 5-10 column volumes of washing buffer 1 (50 mM PB, pH 7.8, 0.3 M NaCl, 5% glycerol) was used to wash the column and
washing solution 1 was stored at 4°C. 4-5 column volumes of washing buffer 2 (50 mM PB, pH 7.8, 0.5 M NaCl, 5% glycerol) was used to wash the column andwashing solution 2 was stored at 4°C. 4-5 column volumes of elution buffer (50 mM Glycine.HCl, pH 3.0, 0.3 M NaCl, 5% glycerol) was used to wash the column, the eluate was collected and neutralization buffer (1 M Tris.HCl pH 8.0) was added, and dialysed against dialysis liquid (50 mM PB, pH 7.8, 0.3 M NaCl, 5% glycerol) overnight at 4 °C, and stored. A small amount of sample was taken and subject to SDS PAGE electrophoresis. Electrophoresis results shown inFigure 2 demonstrate that the molecular weight of the target band in the first column is about 20 kD, slightly larger than the theoretical molecular weight of human proBDNF pro-domain of 13 kD. Without limiting to any theory, it may be relevant to the glycosylation of eukaryotically-expressed protein. - PCR amplification was performed by using the following primers and cDNA of rat as template (commercially available from RAYGENE):
- RatproF1 5'GCTGGCTAGCGCGCCCATGAAAGAAGCAAAC3' (SEQ ID NO: 19)
- RatproR1 5'CCGCTCGAG GCGCCGAACCCTCATAGACATG3' (SEQ ID NO: 20)
- Well-grown HEK293F cells (HEK293F, commercially available from LIFE) were seeded into a flask of cell culture at 1 × 106 Cells/ml, and incubated overnight at 37°C, 5% CO2 120 rpm; V5F-cat-pro-domain plasmid obtained in the above step and liposome (293Fectin, commercially available from LIFE) was diluted with DMEM and gently mixed, and incubated at room temperature for 20 mins. The incubated DNA-liposome complex was added into HEK293F cells, and incubated at 37°C, 5% CO2 120 rpm for 72 hr. Cell culture fluid was collected and centrifuged at 4500 g for 15 mins, the supernatant was taken and cells were discarded. 1 ml of proteinA affinity filler (proteinA Agarose, purchased from RAYGENE) was loaded on a column, proteinA affinity column was equilibrated with 5-10 column volumes of lysis buffer (50 mM PB, 0.3M NaCl, 5% glycerol). Upon centrifugation, the supernatant of cell culture flowed through proteinA affinity column at 1 ml/min and the flow-through liquid was stored at 4°C. 5-10 column volumes of PBS (20 mM PB, pH 7.8, 0.15 M NaCl) was used to wash the column and
washing solution 1 was stored at 4°C. 4-5 column volumes of elution buffer (100 mM Glycine.HCl, pH 2.5) was used to wash the column, the eluate was collected and 10% v/v of neutralization buffer (1 M Tris.HCl pH 8.0) was added, and dialysed against dialysis liquid (50 mM PB, pH 7.8, 0.3 M NaCl, 5% glycerol) overnight at 4 °C, and stored. A small amount of sample was taken and subject to SDS PAGE electrophoresis. Electrophoresis results shown inFigure 3 demonstrate that the molecular weight of the target band in the first column is about 44.3 kD, comparable to the theoretical molecular weight of rat proBDNF pro-domain-Fc. - The 1 ml of purified proBDNF protein (1.0 mg / mL) obtained in Example 1 as an antigen was completely emulsified and mixed with 1 mL of complete Freund's adjuvant (commercially available from by Sigma-Aldrich), and subcutaneously used to immunize 6-8 week-old BALB/c mice, 100 µg of human proBDNF antigen per mouse. After 4 weeks, human proBDNF antigen was emulsified and mixed with incomplete Freund's adjuvant, and used to immunize mice via intraperitoneal injection, per mouse. After an interval of 2 weeks, 50 µg of antigen was used for booster immunization via intraperitoneal injection. 1 week after the 4th booster immunization, purified human proBDNF pro-domain obtained in Example 2 was used for coating, mouse anti-serum titer was detected by ELISA. Booster immunization was continued until mouse anti-serum titer > 105. 3 weeks after the last booster immunization, 20 µg of human proBDNF pro-domain as said above was used for immunization in spleen and stored until use.
- 4 days after booster immunization in spleen, spleen was taken under sterile conditions. Lymphocytes were isolated through a 100 mesh filter, fused with myeloma cell line SP2/0, and selectively cultured with hypoxanthine, aminopterin and thymidine (HAT) for 3 days. Afterwards, HT medium was supplemented, and cultured for another week. Human proBDNF ahtigen of the above Examples of the present invention was used for coating, and positive clones were screened through ELISA, and subcloned for 3 times through limiting dilution, and cultured for another 2 months, and finally obtained a stable hybridoma cell line (each clone named as: 2B11, 2C7, 5C10, 4C3 , 6F3, 2F3, 8E1, 1G7).
- Colnes of hybridoma cells as said above were taken and used to intraperitoneally inject mice in each group at 5 × 105 cells / mouse for preparing ascites. 100 ml of ascites was taken, and diluted in 2 volumes of 0.06 M sodium acetate buffer pH 4.0. 4% octanoic acid was slowly added dropwise with stirring, and stirred for 30 mins. The obtained turbid liquid was centrifuged at 10000 g for 30 mins. The precipitate was discarded, and the supernatant was dialyzed overnight against 0.01 M phosphate buffer, pH 7.4. The dialysate was taken, and an equal volume of saturated ammonium sulfate was slowly added, and placed for 2 hours. The turbid liquid was centrifuged at 10000 g for 10 mins. The supernatant was discarded, and the precipitate was dissolved with 0.01 M PBS, pH 7.4. Upon dissolution, the solution was dialyzed against 0.01 M PBS, pH 7.4, during which the dialysis liquid was changed twice (the time interval for changing dialysis liquid shall not be less than 5 hours). The dialysate was centrifuged at 10000 g for 10 mins, the precipitate was discarded and the supernatant was collected.
- Protein G affinity column (purchased from GE) was used. The column was warmed to room temperature, and equilibrated with 5 column volumes of PBS (0.01 M PB, 0.15 M NaCl, pH 7.4). The collected supernatant as said above was loaded, and 5 column volumes of PBS was used for washing. The column was eluted by 0.1 M glycine-hydrochloric acid solution, pH 2.3 and the eluate was neutralized by 1/10 volume of 1 M disodium hydrogen phosphate solution, pH 9.0. The solution was dialyzed against 0.01 M PBS, pH 7.4, during which the dialysis liquid was changed twice (the time interval for changing dialysis liquid shall be more than 5 hours). The dialysate was centrifuged at 10000 g for 10 mins, the supernatant was filtered through a 0.22 um membrane and stored, thereby obtaining purified monoclonal antibody produced by each corresponding clone.
- Experiment group 1: purified human proBDNF protein obtained in Example 1 was diluted in PBS (0.01 M PB, 0.15 M NaCl, pH 7.4). There are 8 wells for each group corresponding to 8 purified monoclonal antibodies which will be subsequently added, respectively.
- Experiment group 2: purified human proBDNF pro-domain obtained in Example 2 was diluted in PBS (0.01 M PB, 0.15 M NaCl, pH 7.4). There are 8 wells for each group corresponding to 8 purified monoclonal antibodies which will be subsequently added, respectively.
- In
Experiment groups Experiment groups - As shown in
FIG. 4 , purified monoclonal antibodies 2B11 binds to human proBDNF and human proBDNF pro-domain, which demonstrates that the antibody 2B 11 binds to the common segment of both of the proteins, that is, the region of human proBDNF pro-domain. - At 4°C, 10 mg of horseradish peroxidase (HRP) was dissolved in 1 ml of water, and 1 ml of 0.5 M NaIO4 was added for 30 mins. At 4°C, 1 ml of 0.16 M ethylene glycol was added for 30 mins. 10 mg of 2B11 antibody was dialyzed against 0.05 M carbonate buffer pH 9.5, oxidated HRP and 2B11 antibody were mixed and dialyzed at 4°C overnight. 0.4 ml of 1 mg/ml NaBH4 was added and stirred at 4°C for 2 hours. NaH2PO4 solution of low concentration was used to adjust pH at weak acid, and an equal volume of glycerol was added and stored until use.
- Experiment group 1: purified human proBDNF protein obtained in Example 1 was diluted in PBS (0.01 M PB, 0.15 M NaCl, pH 7.4).
- Experiment group 2: prokaryotically-expressed mouse proBDNF (purchased from Alomone labs) was diluted in PBS (0.01 M PB, 0.15 M NaCl, pH 7.4).
- Experiment group 3: rat proBDNF pro-domain eukaryotically-expressed in Example 3 was diluted in PBS (0.01 M PB, 0.15 M NaCl, pH 7.4). 50 ul (50 ng) of diluted protein in
Expeiment group - As shown in
FIG. 5 , clone 2B11 binds to human proBDNF prepared in Example 1 and commercially purchased murine proBDNF as well as rat proBDNF pro-domain eukaryotically-expressed in Example 3. - 6 experiment groups were established according to the number of isotyping antibodies, wherein, in each group, 50 ul of diluted prokaryotically-expressed human proBDNF protein (50 ng) was added into each well for coating overnight at 4°C . The supernatant was discarded, each well was washed with PBS (0.01 M PB, 0.15 M NaCl, pH 7.4) for 2 times, and blocked with PBS containing 5% milk powder at 37°C for 2 hours. The supernatant was discarded, and 50 ul of diluted 2B11 antibody purified as above (1 ug/ml) was added into each well at 37 °C for 1 hour. Afterwards, the supernatant was discarded, each well was washed with PBST containing 0.5% Tween-20 for 3 times, and for Experiment groups 1-6, corresponding 6 isotyping antibodies (purchased from Sigma-Aldrich) were added respectively: goat anti-mouse IgGl , goat anti-mouse of IgG2a , goat anti-mouse IgG2b , goat anti-mouse IgG3 , goat anti-mouse IgA and goat anti-mouse IgM, at 37°C for 1 hr. The supernatant was discarded, each well was washed with PBST containing 0.5% Tween-20 for 3 times, and 50 ul of HRP-labeled donkey anti-goat secondary antibody was added at 37°C for 1 hour. The supernatant was discarded, each well was washed with PBST containing 0.5% Tween-20 for 5 times, ABTS chromogenic substrate was added and developed for 15 minutes, and then absorbance value was determined at 405 nm. When the absorbance value is greater than the reading in the negative control well by three times, it was identified as positive. As shown in
FIG. 6 , clone 2B11 was identified as IgGl type. - The sequence of 2B11 was cloned by 5'-RACE method and confirmed by sequencing (details can be found in instructions of Takara 5'-full RACE Kit): 5' phosphate groups exposed in total RNA were dephosphorylated using alkaline phosphatase (CIAP). Total RNA was in an amount of 2 ug, and was recovered by phenol-chloroform extraction after reaction. 5' cap structure of mRNA was removed by using Tobacco Acid Pyrophosphatase (TAP), while remaining a phosphate group. 5' RACE Adaptor is connected to mRNA With T4 RNA ligase, and was recovered by phenol-chloroform extraction after reaction. Reverse transcription reaction was performed with reverse transcriptase, and used primers was Random 9 mers provided in Kit.
- The target gene was PCR-amplified by a high fidelity enzyme with the reverse transcription product as a template, and used primers were as follows:
- 5': 5'RACE Outer Primer (CATGGCTACATGCTGACAGCCTA), provided in Kit; (SEQ ID NO: 19)
- 3':
- Heavy chain: mIgG1-out primer (CCAGAGTTCCAGGTCACTGTCACT) (SEQ ID NO: 20)
- Light chain: m κ -out primer (AGGTGCTGTCTTTGCTGTCCTG) (SEQ ID NO: 21).
- Nested PCR was performed with above-obtained PCR products as templates, and used primers were as follows:
- 5':
- 5'RACE Inner Primer (CGCGGATCCACAGCCTACTGATGATCAGTCGATG); provided in Kit (SEQ ID NO: 22)
- 3':
- Heavy chain: mIgG1-inner primer (CCAGGGTCACCATGGAGTTAGTTT) (SEQ ID NO: 23)
- Light chain: m κ -inner primer (GTTCAAGAAGCACACGACTGAGG) (SEQ ID NO: 24).
- PCR products obtained above through amplification was purified and TA-cloning was performed (pGEM-T the Easy Vector Kit, commercially available from Promega, detailed method can be found in the instructions of the kit), thereby obtaining Teasy-2B11VH and Teasy-2B11V κ vector respectively, which were sequenced to obtain heavy chain and light chain sequences of monoclonal antibodies 2B 11. Heavy chain and light chain sequences are shown in SEQ ID NO: 9 and SEQ ID NO: 10 respectively. According KabatMan, sequences of heavy chain variable region and light chain variable region can be determined as shown in SEQ ID NO: 7 and SEQ ID NO: 8. According to Kabat numbering rule, sequences of CDR1 , CDR2 , CDR3 in heavy chain variable region are shown in SEQ ID NO: 1-3 respectively, and sequences of CDR1 , CDR2 , CDR3 in light chain variable region are determined as shown in SEQ ID NO: 4-6 respectively.
- PCR amplification was performed using following primers with vector Teasy-2B11VH constructed in Example 5 of the present invention as a template,
- 2BVHF (5'-ggctgttcacagcctttcctggtttcctgtct gaggtgaaggtggtggag-3') SEQ ID NO: 25, and
- 2BVHR (5'-cgatgggcccttggtggaggctgaggagacggtgactg-3') SEQ ID NO: 26,
- PCR amplification was performed with antibody vector pH-EGFRvIII (that is, pH-CH12, construction of which can be found in Example 7.1 of
PCT/CN2009/074090 - Primer FcF (5'-gcctccaccaagggcccatcggtcttccccctgg-3') SEQ ID NO: 27, and
- Primer PIHR (5'-cgcttttgagagggagtactcac-3') SEQ ID NO: 28,
- Two PCR amplified fragments as said above were recovered and bridged, and then PCR-amplified using following primers:
- Nhe (5'-cctagctagccaccatgagagtgctgattcttttgtggctgttcacagcctttcct-3') SEQ ID NO: 29, and
- Primer PIHR as mentioned above SEQ ID NO: 28.
- Products were recovered from agarose gel, dual-digested by NheI and Notl (commercially available from NEB), and connected to vector pH which was dual-digested by the same enzymes to obtain expression plasmid pH-CH2B11 containing chimeric 2B11 heavy chain, which was identified through PCR and confirmed through sequencing.
- PCR amplification was performed using following primers with Teasy-2B11V κ constructed in Example 5 of the present invention as a template,
2BV κ F (5'-cttgcattcttgttgctttggtttccaggtgcaagatgtgacatccagatgactc-3') (SEQ ID NO: 30), and
2BV κ R (5'-agccaccgtacgttttatttccaactttg-3') (SEQ ID NO: 31),
thereby obtaining light chain variable region of monoclonal antibody 2B11. Fragments were recovered and amplified using following primers,
Eco (5'-gatcgatatccaccatggacatgatggtccttgctcagtttcttgcattcttgttg-3'), (SEQ ID NO: 32), and 2BV κ R (SEQ ID NO: 31). - Obtained amplified products were recovered from agarose gel, dual-digested by EcoRV and BsiWI (commercially available from NEB), and connected to vector pK which was dual-digested by the same enzymes to obtain expression plasmid pK-CH2B11 containing chimeric 2B11 light chain, which was identified through PCR and confirmed through sequencing.
- Example 7. Construction of chimeric antibody CH2B11 and preliminary identification of
- The expression vectors above constructed pH-CH2B11 and pK-CH2B11 were used to co-transfect CHO cells in suspension fro expression, and after 3 days, culture supernatant was collected. Expressed chimeric antibody CH2B 11 was contained in the supernatant of cultured CHO cells.
- The supernatant of cultured cells was taken for ELISA binding assay. The method was substantially identical with that in Example 4.4 of the present invention, except that only
Experiment group 1 was included wherein human proBDNF prepared in Example 1 of the present invention was used for coating, and in each well, serial dilutions of cell supernatant of this Example were added instead of clones of corresponding 8 monoclonal antibodies. Similarly, when the absorbance value is greater than the reading in the negative control well by three times, it was identified as positive. Experiment results are shown inFIG. 7 , for chimeric antibody CH2B1, the supernatant of cultured CHO cells in a dilution of 1:32 still exhibited binding activity to human proBDNF. - SD rats (weighing 200-250 g) were divided into 2B11 group and control group (in this experiment, the same volume of PBS was used as a control group). Modeling was mainly established by injecting 50 ul of 1% formalin into planta pedis of a mouse. At 0.5 hours before modeling, 2B11 (75 µg/kg) or placebo in an equal amount was injected via tail vein. Administration via tail vein was performed as follows: tail of a rat was washed with warm water, the site for injection was disinfected by using iodine complex, and 1 ML sterile syringe loaded with an injection dosage of antibody was used to puncture the tail vein at an angle about 10 degree parallel to the tail with slightly negative pressure. When there was a breakthrough sense and dark red blood flowed back into the syringe, 2B11 was injected in a concentration of 500 ug/kg and a total amount of 300 µ L. Modeling method of formalin inflammatory pain can be mainly found in Bellasio S et al., that is, a mouse is firstly placed in a transparent Plexiglas box (30 × 20 × 20 cm) for adapting for 30 mins, and afterwards, 50 ul of 1% formalin solution is injected into planta of its right hind foot via subcutaneous injection. Upon injection, the mouse is immediately placed back into the box, the time of the mouse licking and biting the injected foot was recorded for 1 hour with 5 mins as time interval. Subcutaneous injection of formalin in plantar is a classic model of acute inflammatory pain, and in the model, there will be a special animal spontaneous pain behavior, that is, licking and biting foot. And the longer the time of licking or biting foot, the higher the intensity of pain. Such spontaneous pain behavior can generally be divided into two phases, the first phase appears at 0-5 mins after injection, the second phase appears at 15-60 mins after injection, and there will be an intermittent period between the two phases, wherein the second phase is considered as being relevant to pain sensitization (central sensitization) mechanism.
- According to
FIG. 8 and corresponding data in the following table 1, it is shown that, in 2B11 group, the licking time of the first phase is shorter than that of the control group; while for the second phase, the licking time of the animal in 2B 11 group is significantly reduced as compared with the control group, indicating that 2B 11 possesses obvious analgesic effect on the formalin-caused second phase. (**, P<0.01, compared with the control group).Table 1 Licking time of the control group (sec) Licking time of 2B11 group (sec) Means Means 0-5 min 75 64 104 104 85 78 85.0 54 71 64 65 58 45 59.5 5-10 min 39 19 25 25 34 34 29.3 9 22 0 6 15 12 10.7 10-15 min 2 0 39 29 23 36 21.5 2 0 10 0 0 7 3.2 15-20 min 0 0 9 7 5 21 7.0 44 0 32 0 0 0 12.7 20-25 min 52 33 82 82 75 67 65.2 0 0 0 0 5 6 1.8 25-30 min 13 23 33 54 65 45 38.8 0 2 10 1 8 5 4.3 30-35 min 16 45 65 65 45 56 48.7 9 1 0 0 5 10 4.2 35-40 min 16 0 0 0 21 12 8.2 0 0 0 0 6 10 2.7 40-45 min 2 0 9 9 10 12 7.0 0 0 43 5 21 8 12.8 45-50 min 0 0 0 0 5 0 0.8 0 1 0 0 6 10 2.8 50-55 min 0 0 0 0 6 0 1.0 0 0 0 9 10 0 3.2 55-60 min 27 0 2 2 5 3 6.5 6 0 14 0 0 5 4.2 - The present experiment observes effects of 2B 11 on CFA-induced chronic inflammatory pain. Pain induced by plantar injection of CFA is a classic model of chronic inflammatory pain, which is of long duration. Upon plantar injection of CFA, mechanical pain threshold of the rats is reduced for over 3 weeks.
- Experiment grouping is the same as Example 8.1. The day before modeling, Von Frey filaments method was employed to observe Paw Withdrawal Threshold (PWT). Von frey filament was designed in 1896 by Maximilian von Frey, which is a tactile measuring device. Contacting wires were made of nylon filaments of different diameters, and when using these filaments, they come into contact with the skin (or other sites to be tested, such as planta of an animal) and the filaments were bent to form S-shape by applying a force. Since the strength for bending the filaments can be considered as being continuous, these filaments can accurately reflect the strength applied to the area to be measured. Currently, Von frey filament is one of the most commonly used tools for measuring all kinds of post-pain mechanical hyperalgesia.
- The method for measuring pain threshold by using von frey filaments on rat or mouse's hind legs are described in detail as follows:
- According to the method of Chapland et al., rats were placed on an elevated grid-like metal mesh, so that the hind planta can be freely accessible to the operator, the rats were covered with a transparent organic glass shield, and the rats adapted to the environment for 30 mins before the start of the experiment, until carding and exploration activities of the rats substantially disappeared. The experiment was performed at 8: 00-16: 00, when the brightness is sufficient, the environment is quiet, and the temperature is suitable.
- Before the start of the experiment, the Up and Down method [dixon, Dixon WJ. Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol, 1980, 20: 441-62] was employed, and 9 Von frey filaments with different intensities (0.6, 1, 1.4, 2, 4, 6, 8, 10, 15 g) was used to bottom-up and vertically stimulate central region of plantar surface of rat's injured lateral paw (started from 2G). The filaments were bent to form S-shape for 6-8 seconds with an interval of 30 seconds between two adjacent stimulus for returning the behavioral response caused by the last stimulus to normal. Flinching reflex of rat's injured lateral paw was observed, and a positive reaction was recorded if quick flinching reflex appears during the stimulation time or immediately after the removal of von Frey filaments. However, flinching reflex caused by physical activities such as movement, can not be recorded as a positive reaction, and under such situation, the measurement shall be repeated. If the rat does not exhibit such positive reaction, a filament with a larger scale will be selected to stimulate the rat's planta; if the rat exhibits such positive reaction, a filament with a smaller scale will be selected to stimulate the rat's planta, and so on, wherein upper and lower limits of the stimulus were 15 G and 0.6 G respectively. 50% PWT was calculated according to Up and down method recommended by Dixon. A positive reaction was recorded if quick flinching reflex or licking response appears during the detection or at the moment when von Frey filaments were removed, and represented as "X". If no response was observed, it is deemed as a negative reaction, and represented as "O". According to the above test method, a sequence consisting of a combination of "O" and "X" can be obtained. "O" in front of "X" was deemed as starting point, and 6 consecutive stimulating responses were selected, such as "OXOXOO", as the key sequence for estimating 50% PWT. However, the sequence composition is not only fixed to 6 times. According to the response from rats to filaments with different intensities, the minimal sequence composition can be 4 times, such as "XXXX", wherein stimulus of rats occurred in a range of 2.0-0.6 g were positive; or can be 6 times, wherein stimulus occurred in a range of 2.0-0.6 g were negative. 50% PWT of rats with continuous positive or negative response were identified as 0.6G and 15G; and 50% PWT of rats with positive and negative response were calculated according to the following equation:
-
- In each experiment group, 100 µL of CFA was injected to mice at planta, and then 2B11 (75 µg/kg/day) or PBS were given via tail vein, one time every 12 hours until the 5th day after the injection of CFA. Upon injection, changes in PWT were observed at different time periods to the fifth day after operation.
- According to
FIG. 9 and corresponding data in the following table 3, it is shown that, in the blank control group, after injection of CFA at planta, withdrawal threshold PWT of hind paw was significantly reduced, compared with baseline value, until the 5th day after the injection; while in the 2B11 group, at the 2nd day after injection of CFA, the pain threshold of mice was significantly improved, compared with the blank control group, PWT values gradually increased, and at the 5th day after injection, in 2B11 group, PWT was significantly higher than that in the blank control group, which demonstrates that 2B11 can significantly reduce chronic inflammatory pain caused by CFA (Figure 9 ). *, P <0.05, compared with control group; **, P <0.01 compared with the control group.Table 3 Paw withdrawal threshold, control group (g) Paw withdrawal threshold, 2B11 group (g) Means Means Baselin e value 15 15 15 15 12.9 9 8.6 1 10.0 4 13.1 15 15 15 11.8 8 15 7.53 12.9 9 13.2 3 hr 1.7 2 1.5 8 0.6 1.0 8 1.46 0.9 2 0.99 1.2 3.3 3 1.5 8 2.2 7 1.72 0.6 2.27 0.6 1.8 1 d 1.2 2 2.2 7 2.7 0.8 6 0.92 1.2 2 7.8 2.4 2.2 7 0.6 1.9 1 1.46 1.22 10.0 4 6.17 3.4 2d 1.0 8 5.0 4 1.2 2 1.9 1 0.6 1.6 1 2.47 2.0 3.7 3 2.0 3 4.4 0.82 4.25 8.44 4.25 4.0 3 d 2.2 7 2.2 7 2.8 1 0.8 6 0.86 2.8 1 1.91 2.0 5.0 4 5.0 4 6.6 4 2.03 6.64 11.6 9 7.53 6.4 4d 6.6 6 2.8 1 2.3 7 3.3 3 1.91 1.4 5 3.13 3.1 7.8 3.5 8 8.4 4 2 10.0 4 10.6 9 4.47 6.7 5d 2.8 1 2.2 7 3.7 3 1.5 8 1.01 2.3 6.5 8 15 5.5 7 4.98 2.27 6.9 - Cutting pain model of rat hind paws is the most commonly used animal model for surgical pain. After cutting at hind paws, rats elevate the cut limb, can not bear weight, while lick the paw. Therefore, pain score is often used to elevate the degree of cutting pain. Rats were observed for grounding situation, every 5 minutes (generally calculated in hours). If the hind paw was always elevated, it will be given 2 points; if the rat can ground, but can not bear weight (whether the mesh of the cage is deformed is used as a criterion), it will be given 1 point; and if the rat can completely ground and bear weight, it will be given 0 point. The higher the score, the stronger the degree of pain. Cumulative Pain Score (CPS) is often employed to evaluate the degree of cutting pain of foot. The higher the CPS, the stronger the intensity of pain. On the other hand, after cutting, mechanical pain threshold will fall accordingly. Therefore, we use these two methods to evaluate effects of proBDNF monoclonal antibody (2B11) on cutting pain.
- Experiment grouping is the same as Example 8.1. At 15 minutes before the operation, 500 ug/kg of 2B11 was given via intravenous injection. Rats were observed for pain score (
Fig. 10 and following table 4) and mechanical pain threshold of hind paw (Figure 11 and following table 5) at different time periods after operation, and it can be found that:
In 2B 11 experiment group, pain scores of mouse measured at 1 hour after the cutting operation were significantly lower compared with the mouse in the control group, wherein the difference at 3 hour after the cutting operation was the most significant. And pain scores measured at 6 hour after the cutting operation were still significantly lower than those of the control group.Table 4 Pain scores of 2B11 group (cps) Pain scores of control group (cps) Means Means 1hr 1 20 9 15 3 9.6 5 9 24 12 5 11 3hr 4 11 9 8 4 7.2 21 13 24 20 16 18.8 6hr 1 17 7 1 2 5.6 8 13 18 16 7 12.4 24hr 2 22 2 0 3 5.8 0 0 9 7 1 3.4 - In 2B 11 experiment group, mechanical pain threshold of mouse measured at 1 hour after the cutting operation were significantly lower compared with the mouse in the control group.
Table 5 Paw withdrawal threshold, 2B11 group (g) Paw withdrawal threshold, control group (g) Means Means Baseline value 7.8 4.25 4.25 4.74 8 6.23 5.88 8.61 4.25 7.8 6.81 4.56 6.81 6.47 3hr 4.25 2.75 2.1 2.03 4.14 2.65 2.99 0.89 0.6 0.6 0.6 1.45 1.1 0.87 6hr 2.81 1.22 3.73 3.58 4.72 3.21 3.21 0.86 1.45 0.6 2.03 2.27 2.03 1.54 24hr 2.03 4.7 1.99 5.56 6.17 5.23 4.28 2.27 1.36 2 2.37 4.25 2.37 2.44 - From the results of the above Table 4 and 5, it is demonstrated that the monoclonal antibody 2B11 of the invention has a good and significant analgesic effect on cutting pain.
- Upon intraperitoneal injection of acetic acid, mice mainly exhibit writhing responses, such as abdominal contraction, stretching (Writhing Test), especially at 1 hour after injection. Observation of writhing responses during 1 hour after the injection of acetic acid is a commonly used model for screening analgesics. Intraperitoneal injection of 0.6% acetic acid (0.2 ml) per mouse will cause chemical visceral pain.
- Experiment grouping is the same as Example 8.1. At 30 minutes before the injection of acetic acid, monoclonal antibody 2B11 (500 ug/kg, 0.2 ml) or placebo in the same volume (herein referring to PBS) was given to mice in each experiment groups via intraperitoneal injection respectively. According to
FIG. 12 and corresponding data in the following table 6, it is shown that, compared with the mice in the control group, writhing responses of the mice in 2B 11 group are significantly reduced, which demonstrates that pre-treatment of monoclonal antibody 2B11 of the present invention can reduce visceral pain induced by intraperitoneal injection of acetic acid.Table 6 Writhing response in control group (time/hour) Writhing response in 2B11 group (times/hour) 117 74 78 58 90 57 95 47 137 62 89 53 101 22 Means 101 53.3
Claims (17)
- An antibody polypeptide that specifically recognizes amino acids at positions 19-128 of pro-BDNF pro-domain, including1) a heavy chain variable region comprising the following amino acid sequence:(a) CDR1 region of SEQ ID NO: 1,(b) CDR2 region of SEQ ID NO: 2,(c) CDR3 region of SEQ ID NO: 3; and / or2) a light chain variable region comprising the following amino acid sequence:(d) CDR1 region of SEQ ID NO: 4,(e) CDR2 region of SEQ ID NO: 5,(f) CDR3 region of SEQ ID NO: 6.
- The antibody polypeptide of claim 1, wherein the antibody polypeptide is a monoclonal antibody.
- The antibody polypeptide of claim 1 or 2, wherein the amino acid sequence of heavy chain variable region is SEQ ID NO: 7.
- The antibody polypeptide of claim 3, wherein the amino acid sequences of light chain variable region is SEQ ID NO: 8.
- The antibody polypeptide of claim 1 or 2, wherein the amino acid sequence of heavy chain is SEQ ID NO: 9.
- The antibody polypeptide of claim 5, wherein the amino acid sequence of light chain is SEQ ID NO: 10.
- The antibody polypeptide of claim 2, wherein the antibody polypeptide is selected from a humanized antibody polypeptide, a chimeric antibody polypeptide, an affinity maturated antibody polypeptide or one or more combinations thereof.
- An antibody polypeptide, wherein the antibody polypeptide is an antibody polypeptide competing with the antibody polypeptides of any one the above claims.
- A nucleic acid sequence encoding the antibody polypeptide of any one of the preceding claims.
- The nucleic acid sequence of claim 9, wherein the nucleic acid encoding the amino acid sequence of heavy chain variable region of the antibody polypeptide is SEQ ID NO: 11, and the nucleic acid encoding the amino acid sequence of light chain variable region of the antibody polypeptide is SEQ ID NO: 12.
- The nucleic acid sequence of claim 10, wherein the nucleic acid encoding the amino acid sequence of heavy chain of the antibody polypeptide is SEQ ID NO: 13, and the nucleic acid encoding the amino acid sequence of light chain of the antibody polypeptide is SEQ ID NO: 14.
- A vector comprising the nucleic acid sequence of any one of claims 9-11.
- A host comprising the vector of claim 12.
- Use of one or more of antibody polypeptides specifically recognizing pro-BDNF pro-domain in the preparation of a medicament to mitigate and / or inhibit chronic pain selected from the following group: chronic inflammatory pain, phantom limb pain, painful diabetic neuropathy, neuropathic pain, chronic lumbodorsalgia, chronic visceral pain, cancer pain, arthritis pain, craniofacial pain, trigeminal neuralgia, migraine, complex regional pain syndrome, and a combination thereof.
- Use of one or more of antibody polypeptide of any one of claims 1-8 in the preparation of a medicament to mitigate and / or inhibit pain selected from the following group: post-operative pain, acute inflammatory pain, chronic inflammatory pain, phantom limb pain, painful diabetic neuropathy, neuropathic pain, chronic lumbodorsalgia, chronic visceral pain, cancer pain, arthritis pain, craniofacial pain, trigeminal neuralgia, migraine, complex regional pain syndrome, and a combination thereof.
- A pharmaceutical composition comprising an effective amount of the antibody polypeptide of any one of claims 1-8.
- The pharmaceutical composition of claim 16, which is administered by intravenous or intraperitoneal injection.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410015890.3A CN104774264B (en) | 2014-01-15 | 2014-01-15 | Anti-human proBDNF monoclonal antibodies and its effect in pain |
PCT/CN2015/070011 WO2015106641A1 (en) | 2014-01-15 | 2015-01-04 | Anti-human probdnf monoclonal antibody, and uses thereof in pains |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3095796A1 true EP3095796A1 (en) | 2016-11-23 |
EP3095796A4 EP3095796A4 (en) | 2017-11-22 |
EP3095796B1 EP3095796B1 (en) | 2020-10-28 |
Family
ID=53542390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15737195.6A Not-in-force EP3095796B1 (en) | 2014-01-15 | 2015-01-04 | Anti-human probdnf monoclonal antibody, and uses thereof in pains |
Country Status (5)
Country | Link |
---|---|
US (1) | US9969799B2 (en) |
EP (1) | EP3095796B1 (en) |
JP (1) | JP6463377B2 (en) |
CN (1) | CN104774264B (en) |
WO (1) | WO2015106641A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3235507A4 (en) * | 2014-12-19 | 2018-06-20 | Shanghai Yile Biotechnology Co., Ltd. | Application of binding molecule for specific binding of precursor for brain-derived neurotrophic factor |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106466479A (en) * | 2015-08-18 | 2017-03-01 | 周意 | Brain Derived Neurotrophic Factor precursor protein is used as the target spot for the treatment of affective disorder |
JP2020531041A (en) * | 2017-08-28 | 2020-11-05 | 上海易楽生物技術有限公司 | Polypeptides and antibodies that bind to polypeptides |
WO2019152715A1 (en) | 2018-01-31 | 2019-08-08 | Alector Llc | Anti-ms4a4a antibodies and methods of use thereof |
CN112204050A (en) * | 2018-01-31 | 2021-01-08 | 艾莱克特有限责任公司 | anti-MS 4A6A antibodies and methods of use thereof |
WO2019184920A1 (en) * | 2018-03-26 | 2019-10-03 | 上海易乐生物技术有限公司 | Use of probdnf regulator in b cell-related diseases |
CN114341181A (en) | 2019-07-31 | 2022-04-12 | 艾莱克特有限责任公司 | anti-MS 4A4A antibodies and methods of use thereof |
CN113456799A (en) * | 2020-12-25 | 2021-10-01 | 苏州澳宗生物科技有限公司 | Application of p75ECD in preparing medicine for regulating pain |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
AU631545B2 (en) | 1988-04-15 | 1992-12-03 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
JP3068180B2 (en) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | Generation of heterologous antibodies |
ES2301158T3 (en) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | XENOGENIC ANTIBODY PRODUCTION. |
DE69637481T2 (en) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Human antibodies to IL-8 derived from immunized Xenomae |
US7507799B2 (en) * | 2001-05-25 | 2009-03-24 | Cornell Research Foundation, Inc. | High affinity ligand for p75 neurotrophin receptor |
US8066997B2 (en) * | 2002-12-20 | 2011-11-29 | Anders Nykjaer | Modulation of activity of neurotrophins |
EP1988920A1 (en) * | 2006-02-02 | 2008-11-12 | Rinat Neuroscience Corp. | Methods for treating obesity by administering a trkb antagonist |
WO2008002572A2 (en) * | 2006-06-27 | 2008-01-03 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Method for measuring mature brain derived neurotrophic factor |
RS60019B1 (en) * | 2006-12-21 | 2020-04-30 | H Lundbeck As | Modulation of activity of proneurotrophins |
-
2014
- 2014-01-15 CN CN201410015890.3A patent/CN104774264B/en active Active
-
2015
- 2015-01-04 WO PCT/CN2015/070011 patent/WO2015106641A1/en active Application Filing
- 2015-01-04 JP JP2016564368A patent/JP6463377B2/en not_active Expired - Fee Related
- 2015-01-04 US US15/112,109 patent/US9969799B2/en active Active
- 2015-01-04 EP EP15737195.6A patent/EP3095796B1/en not_active Not-in-force
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3235507A4 (en) * | 2014-12-19 | 2018-06-20 | Shanghai Yile Biotechnology Co., Ltd. | Application of binding molecule for specific binding of precursor for brain-derived neurotrophic factor |
US10556947B2 (en) | 2014-12-19 | 2020-02-11 | Shanghai Yile Biotechnology Co., Ltd. | Binding molecule that binds specifically to the precursor of brain-derived neurotrophic factor |
Also Published As
Publication number | Publication date |
---|---|
EP3095796B1 (en) | 2020-10-28 |
JP2017504357A (en) | 2017-02-09 |
JP6463377B2 (en) | 2019-01-30 |
WO2015106641A1 (en) | 2015-07-23 |
CN104774264A (en) | 2015-07-15 |
EP3095796A4 (en) | 2017-11-22 |
US9969799B2 (en) | 2018-05-15 |
US20160376359A1 (en) | 2016-12-29 |
CN104774264B (en) | 2018-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3095796B1 (en) | Anti-human probdnf monoclonal antibody, and uses thereof in pains | |
EP3498732B1 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
KR101637502B1 (en) | Therapeutic canine immunoglobulins and methods of using the same | |
US20190276525A1 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
KR102166083B1 (en) | Antibodies to bradykinin b1 receptor ligands | |
KR20180002711A (en) | Treatment or prevention of migraine headache | |
CN101014364A (en) | Anti-ngf antibodies and methods using same | |
CN104955838A (en) | Bispecific EGFR/c-Met antibodies | |
CA2835094C (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
US20230002500A1 (en) | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies | |
JP2018505853A (en) | Anti-TrkA antibodies and derivatives thereof with enhanced inhibitory properties for use in the treatment of bone-related pain | |
US9249224B2 (en) | Human growth hormone receptor antagonist antibodies and methods of use thereof | |
US20230235073A1 (en) | Anti-cd36 antibodies and their use to treat cancer | |
US8163285B2 (en) | Nogo-A binding molecules and pharmaceutical use thereof | |
ES2905682T3 (en) | Anti-nerve growth factor antibodies and methods of preparation and use thereof | |
GB2528811A (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
NZ617447B2 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
NZ617448B2 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20160812 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: WANG, HUAMAO Inventor name: LI, ZONGHAI Inventor name: DAI, RUPING |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20171024 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 15/63 20060101ALI20171018BHEP Ipc: C07K 16/22 20060101AFI20171018BHEP Ipc: A61K 39/395 20060101ALI20171018BHEP Ipc: C12N 15/13 20060101ALI20171018BHEP Ipc: A61P 25/04 20060101ALI20171018BHEP Ipc: A61K 39/00 20060101ALI20171018BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20180816 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/22 20060101AFI20200414BHEP Ipc: A61P 29/00 20060101ALI20200414BHEP Ipc: A61K 39/00 20060101ALI20200414BHEP Ipc: A61P 25/04 20060101ALI20200414BHEP |
|
INTG | Intention to grant announced |
Effective date: 20200518 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602015061128 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1328141 Country of ref document: AT Kind code of ref document: T Effective date: 20201115 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1328141 Country of ref document: AT Kind code of ref document: T Effective date: 20201028 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20201028 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210301 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210128 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210129 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210228 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210128 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602015061128 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210104 |
|
26N | No opposition filed |
Effective date: 20210729 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20210131 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210131 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210131 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210104 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20220119 Year of fee payment: 8 Ref country code: DE Payment date: 20220119 Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210228 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20220119 Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210131 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20150104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602015061128 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20230104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230104 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230801 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230131 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201028 |